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A B S T R A C T
Background
Dysarthria is an acquired speech disorder following neurological injury that reduces intelligibility of speech due to weak, imprecise, slow
and/or unco-ordinated muscle control. The impact of dysarthria goes beyond communication and affects psychosocial functioning.
This is an update of a review previously published in 2005. The scope has been broadened to include additional interventions, and the
title amended accordingly.
Objectives
To assess the effects of interventions to improve dysarthric speech following stroke and other non-progressive adult-acquired brain
injury such as trauma, infection, tumour and surgery.
Search methods
We searched the Cochrane Stroke Group Trials Register (May 2016), CENTRAL (Cochrane Library 2016, Issue 4), MEDLINE,
Embase, and CINAHL on 6 May 2016. We also searched Linguistics and Language Behavioral Abstracts (LLBA) (1976 to November
2016) and PsycINFO (1800 to September 2016). To identify further published, unpublished and ongoing trials, we searched major
trials registers: WHO ICTRP, the ISRCTN registry, and ClinicalTrials.gov. We also handsearched the reference lists of relevant articles
and contacted academic institutions and other researchers regarding other published, unpublished or ongoing trials. We did not impose
any language restrictions.
Selection criteria
We selected randomised controlled trials (RCTs) comparing dysarthria interventions with 1) no intervention, 2) another intervention
for dysarthria (this intervention may differ in methodology, timing of delivery, duration, frequency or theory), or 3) an attention
control.
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Data collection and analysis
Three review authors selected trials for inclusion, extracted data, and assessed risk of bias. We attempted to contact study authors for
clarification and missing data as required. We calculated standardised mean difference (SMD) and 95% confidence interval (CI), using
a random-effects model, and performed sensitivity analyses to assess the influence of methodological quality. We planned to conduct
subgroup analyses for underlying clinical conditions.
Main results
We included five small trials that randomised a total of 234 participants. Two studies were assessed as low risk of bias; none of the included
studies were adequately powered. Two studies used an attention control and three studies compared to an alternative intervention,
which in all cases was one intervention versus usual care intervention. The searches we carried out did not find any trials comparing
an intervention with no intervention. The searches did not find any trials of an intervention that compared variations in timing, dose,
or intensity of treatment using the same intervention. Four studies included only people with stroke; one included mostly people with
stroke, but also those with brain injury. Three studies delivered interventions in the first few months after stroke; two recruited people
with chronic dysarthria. Three studies evaluated behavioural interventions, one investigated acupuncture and another transcranial
magnetic stimulation. One study included people with dysarthria within a broader trial of people with impaired communication.
Our primary analysis of a persisting (three to nine months post-intervention) effect at the activity level of measurement found no
evidence in favour of dysarthria intervention compared with any control (SMD 0.18, 95% CI -0.18 to 0.55; 3 trials, 116 participants,
GRADE: low quality, I² = 0%). Findings from sensitivity analysis of studies at low risk of bias were similar, with a slightly wider
confidence interval and low heterogeneity (SMD 0.21, 95% CI -0.30 to 0.73, I² = 32%; 2 trials, 92 participants, GRADE: low quality).
Subgroup analysis results for stroke were similar to the primary analysis because few non-stroke participants had been recruited to trials
(SMD 0.16, 95% CI -0.23 to 0.54, I² = 0%; 3 trials, 106 participants, GRADE: low quality).
Similar results emerged frommost of the secondary analyses. There was no evidence of a persisting effect at the impairment (SMD 0.07,
95% CI -0.91 to 1.06, I² = 70%; 2 trials, 56 participants, GRADE: very low quality) or participation level (SMD -0.11, 95% CI -0.56
to 0.33, I² = 0%; 2 trials, 79 participants, GRADE: low quality) but substantial heterogeneity on the former. Analyses of immediate
post-intervention outcomes provided no evidence of any short-term benefit on activity (SMD 0.29, 95% CI -0.07 to 0.66, I² = 0%;
3 trials, 117 participants, GRADE: very low quality); or participation (SMD -0.24, 95% CI -0.94 to 0.45; 1 study, 32 participants)
levels of measurement.
There was a statistically significant effect favouring intervention at the immediate, impairment level of measurement (SMD 0.47, 95%
CI 0.02 to 0.92, P = 0.04, I² = 0%; 4 trials, 99 participants, GRADE: very low quality) but only one of these four trials had a low risk
of bias.
Authors’ conclusions
We found no definitive, adequately powered RCTs of interventions for people with dysarthria. We found limited evidence to suggest
there may be an immediate beneficial effect on impairment level measures; more, higher quality research is needed to confirm this
finding.
Although we evaluated five studies, the benefits and risks of interventions remain unknown and the emerging evidence justifies the
need for adequately powered clinical trials into this condition.
People with dysarthria after stroke or brain injury should continue to receive rehabilitation according to clinical guidelines.
P L A I N L A N G U A G E S U M M A R Y
Interventions for speech problems (dysarthria) after stroke or other non-progressive brain injury
Review question
Does any type of treatment help people who have difficulty speaking clearly after a stroke or other types of brain injury acquired during
adulthood?
Background
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Brain damage caused by stroke, injury or other non-progressive disease can make speech unclear and difficult for listeners to understand.
This condition is known as dysarthria and it occurs when face, tongue, and throat muscles are weak, slow, and unco-ordinated.
Dysarthria can cause people who are affected to lose confidence when talking and become socially isolated, even if others see symptoms
as mild. People with dysarthria do not have difficulties thinking, remembering, or retrieving words.
Treatment is usually provided by a speech and language therapist or speech pathologist and involves advice and education plus strategies
and exercises to increase clarity of speech and to cope with social interaction. Other types of treatment used include acupuncture or
brain stimulation.
We wanted to find out if any treatments work, if the effects are long lasting, and if so, which works best, when treatment should start,
how frequent treatment should be, and for how long. To find out we searched for, evaluated, and summarised the quality of the existing
research on this topic.
Search date
We searched the literature up to May 2016.
Study characteristics
We included five small trials that randomised only 234 people, almost all with stroke. Two trials investigated dysarthria treatment
versus an attention control and three compared one treatment with usual care. There were no trials that compared one treatment to no
treatment.
Key results
We found few randomised controlled trials of dysarthria treatment, and those that have been conducted involved small numbers of
participants, or were not adequately designed or had serious reporting flaws.
We compared many different measures at various time points after treatment, so caution is recommended when interpreting results.
We found no evidence of effectiveness on most measures, including long-lasting improvement in every day communication abilities. A
positive finding was short-term improvement in muscle movement, such as tongue and lip control. However, this result is not reliable
because it was based on small numbers of people, and we found concerns about the conduct and reporting of some trials. This finding
needs to be investigated in a bigger, better designed trial.
We found insufficient evidence to tell us whether any one treatment is better than any other or whether treatment is better than general
support, or no treatment. We found no studies that examined timing, duration, or intensity of treatment. This is a clinically important
question and should be considered in future trials.
Quality of the evidence
The included trials varied in quality but all included small numbers of participants. Overall, studies were rated as low to very low
quality evidence.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Dysarthria intervention compared with another intervention, attention control, placebo or no intervention for people with
dysarthria after stroke or other adult- acquired, non-progressive brain injury
Patient or population: adults with dysarthria following stroke or other adult-acquired, non-progressive brain injury
Settings: any
Intervention: dysarthria intervent ion
Comparison: another intervent ion, attent ion control, placebo or no intervent ion
Outcomes Standardised mean
difference
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Dysarthria intervention
versus any control:
persisting effects, ac-
tivity level
0.18 [-0.18, 0.55] 116 part icipants
3 RCTs
⊕⊕©©
low
Very small numbers
and none of the stud-
ies are adequately pow-
ered
Only two of the three
studies considered low
risk of bias
Dysarthria intervention
versus any control:
persisting effects, im-
pairment level
0.07 [-0.91, 1.06] 56 part icipants
2 RCTs
⊕©©©
very low
Very small numbers,
none of the studies
are adequately pow-
ered. Only one of the
two studies considered
low risk of bias
Dysarthria intervention
versus any control:
persisting effects, par-
ticipation level
-0.11 [-0.56, 0.33] 79 part icipants
2 RCTs
⊕⊕©©
low
Both studies consid-
ered low risk of bias
but very small numbers
and neither study ade-
quately powered
Dysarthria intervention
versus any control for
stroke subgroup: per-
sisting effects, activity
level
0.16 [-0.23, 0.54] 106 part icipants
3 RCTs
⊕⊕©©
low
Very small numbers
and none of the stud-
ies are adequately pow-
ered
Only two of the three
studies considered low
risk of bias
Dysarthria intervention
versus any control: im-
mediate effects, activ-
ity level
0.29 [-0.07, 0.66] 117 part icipants
3 RCTs
⊕©©©
very low
Very small part ici-
pant numbers, not ad-
equately powered. Only
one of the three studies
considered to be low
risk of bias
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Dysarthria intervention
versus any control: im-
mediate effects, im-
pairment level
0.47 [0.02, 0.92] 99 part icipants
4 RCTs
⊕©©©
very low
Very small part ici-
pant numbers, not ad-
equately powered. Only
one of the four studies
considered to be low
risk of bias. This com-
parison shows a signif -
icant ef fect
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and
may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is
likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D
Description of the condition
Dysarthria is a speech disorder affecting intelligibility due to dis-
turbances in neuromuscular control. Dysarthria affects approxi-
mately 20% to 30% of stroke survivors (Lawrence 2001; Lubart
2005; Warlow 2008) and 10% to 60% of those who survive trau-
matic brain injury. It can occur in adults as an outcome of menin-
gitis, encephalitis, post-surgical meningioma, and acoustic neu-
roma (Sellars 2005).
Dysarthria is defined as a neurologic motor speech impairment
causing the speech musculature to be slow, weak and/or impre-
cise (Duffy 2013). This causes poor co-ordination of movements
involving breathing, voice production, resonance, and oral artic-
ulation (Yorkston 1996). People with dysarthric speech typically
sound less intelligible or slurred because of poor oral control of
articulators, particularly the tongue. Speech can also be quiet, un-
derpowered, and lacking expressiveness because of respiratory con-
trol or impaired vocal cord function. Dysarthria includes a wide
severity range; some people may be mostly unintelligible to the lis-
tener; people at the milder end of the range may experience lapses
in speech accuracy, or fatigue, but speech is generally intelligible.
Dysarthria impacts beyond impaired communication. It can neg-
atively affect psychological wellbeing, social participation, and re-
habilitation (Brady 2011; Dickson 2008; Tilling 2001). Brady
2011 found that the psychological impact can be influenced by
pre-morbid levels of communication demands. An individual with
mild dysarthria, but high levels of communication before their ill-
ness, may experience psychological impairment as severe as some-
one with more severe dysarthria.
Description of the intervention
Behavioural interventions by a speech and language therapist or
speech language pathologist are the mainstay of dysarthria treat-
ment. The primary aim is to maximise the patient’s ability to
communicate with others. UK treatment guidelines for dysarthria
(Taylor-Goh2005) recommend that behavioural interventions ad-
dress all dimensions of the International Classification of Func-
tioning, Disability and Health (ICF) Framework; impairment, ac-
tivity and participation (WHO 2001). Impairment level exercises
to improve the strength, speed, or function of the impaired mus-
culature may be used. These are usually non-speech and oro-mo-
tor movements of affected muscles or muscle groups. This may
include external stimulation of the muscles such as applying ice
packs, brushing the skin, acupuncture (traditional and electrical),
or transcranial magnetic stimulation of the brain. At the activity
level, compensatory strategies to increase intelligibility through
purposeful speech production such as over-articulation or slow-
ing rate of speech may be used. In addition alternative ways to
communicate, or support speech, may be used such as an alpha-
bet chart or computers with artificial voice software. Participation
level approaches may use facilitated group work, education, and
feedback to support the psychological health of people living with
dysarthria or advice to a communication partner may be imple-
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mented.
How the intervention might work
The interventions at the impairment level in theDescription of the
intervention are likely to be focused on the recovery of impaired
movement through exercises to increase strength, range, precision
and speed of movement required for speech. Treatment can utilise
non-speech or more typically speech-focused movement tasks. In-
tervention for limb rehabilitation indicates some association be-
tween muscle strength and function of movement (Langhorne
2009) but it is not known whether this is the case for muscles in-
volved in speech. Interventions may examine intensity of interven-
tion and may compare quantity, duration and frequency of input.
We know from post-stroke research more generally that increased
intensity of treatment may be a key element in recovery but the
optimum frequency, duration and quantity of intervention is not
known (Intercollegiate Stroke Working Party 2016).
The interventions at the activity and participation level as out-
lined in the Description of the intervention are likely to focus
on strategies or patient specific goals to improve speech intelli-
gibility that relate to a meaningful communication activity for
that person. Stroke guidance suggests that goal setting should be
used as a rehabilitation tool (Intercollegiate Stroke Working Party
2016).This may include reducing rate of speech when talking on
the phone, employing purposeful use of speech intonation to dis-
tinguish statements from questions in conversation, or advice to
the key communication partner. Group or individual work to tar-
get confidence in use of communication is another treatment ap-
proach, which may incorporate principles of psychological inter-
ventions such as motivational interviewing. Environmental mod-
ification and education can also be utilised to optimise communi-
cation ease and success in a given context such as a family, hospital
or nursing home setting.
Why it is important to do this review
The previous version of this review found no studies that met in-
clusion criteria (Sellars 2005). Further trials have since been pub-
lished, and this update broadened the scope of the search strategy
applied by Sellars 2005 to include all interventions carried out by
any health professional, people with dysarthria, a trained individ-
ual, or any other new approaches to treatment.
O B J E C T I V E S
To assess the effects of interventions to improve dysarthric speech
following stroke and other non-progressive adult-acquired brain
injury such as trauma, infection, tumour and surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of interventions
to improve non-progressive dysarthric speech in adults with ac-
quired brain injuries, including comparisons with no interven-
tion, another intervention (which may be the same intervention
approach but alternative method, theory, timing, duration or fre-
quency), attention control, or placebo. We included data only
from the first phase of cross-over trials to avoid contamination.
Types of participants
Adults (aged over 18 years) diagnosed with non-progressive
dysarthria following acquired brain injury, principally stroke and
traumatic brain injury, at any time since stroke onset or trauma
event.
Types of interventions
We considered any type of intervention for acquired dysarthria
including behavioural or psychological approaches, use of devices
and medication, excluding surgical interventions. Interventions
could be carried out by any healthcare professional, healthcare
staff, trained volunteer, familymember or carer, or the person with
dysarthria.
Interventions addressed any level of the International Classifica-
tion of Functioning Disability and Health (ICF) (WHO 2001)
including the following.
• Impairment level: interventions specifically targeting the
impairment of function, e.g. non-speech and oro-motor exercises
to improve speed, range, strength, accuracy of speech/respiratory
musculature, external stimulation of the muscles such as
applying ice packs, brushing the skin, transcranial magnetic
stimulation of the brain, acupuncture (traditional and electrical).
• Activity level: interventions to increase intelligibility by
modifying existing speech (e.g. modifying rate of speech) or the
use of augmentative or alternative communication devices e.g.
light tech aids (non-technical materials such as an alphabet
chart) and high tech aids (such as text-to-talk computer devices).
• Participation level: interventions aimed at support or
education for the individual with dysarthria or programmes for
people with dysarthria and their conversational partners or
conversational training as well as any psychological approaches to
treatment that focus on increasing social participation.
We did not place any restrictions on frequency, intensity, or dura-
tion of the interventions.
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Types of outcome measures
Primary outcomes
The primary outcome measure for this review was the long-term
effectiveness of the dysarthria intervention on everyday speech (ac-
tivity level, persisting effect) compared with any control (another
intervention, attention control or placebo, or no intervention).
Attempts to objectively measure everyday speech are usually based
on listener perception grading scales such as dysarthria therapy
outcome measures (Enderby 1997) or the communication effec-
tiveness measure (Mackenzie 2007).We defined evidence of a per-
sistent beneficial effect as around six months post-intervention ex-
tracted as measures taken between three and nine months post-
intervention.
When trials used more than one outcome measure at the activity
level, we took the primary outcome as specified by the trial inves-
tigators. If a trial had not specified a primary outcome measure,
we checked if a measure of functional communication had been
used at the specified time points.
Secondary outcomes
Secondary outcomes included exploring effects:
• at other measurement levels (e.g. impairment,
participation);
• at other time points (e.g. immediate post-intervention);
• compared with specific control groups (e.g. another
intervention, attention control or placebo, or no intervention);
• for clinical subgroups (e.g. stroke, brain injury);
• for studies assessed at low risk of bias.
Secondary outcome measures were as follows.
• Communication at impairment level (immediate and
persisting): speech impairment measure e.g. Frenchay Dysarthria
Assessment edition I or II (Enderby 1983), Iowa Oral
Performance Instrument (IOPI) (IOPI 2005), measures of
intelligibility (e.g. Assessment of intelligibility of Dysarthric
Speech) (Yorkston 1984), acoustic and perceptual measures of
voice and speech (e.g. vocal profile analysis, pitch, loudness, air
flow, sound spectography).
• Communication at activity level (immediate): activity
measure (e.g. Dysarthria Therapy Outcome Measure) (Enderby
1997), listener acceptability measures.
• Communication-related quality of life (immediate and
persisting participation level): patient perception of impact (e.g.
Dysarthria Impact Profile) (Walshe 2009); Communication
Outcomes after Stroke Scale (Long 2008).
• Generic quality of life measures: mood scales (e.g. Hospital
Anxiety and Depression Scale) (Zigmond 1983); subjective
health scales (e.g. EuroQol, SF-36) (Herdman 2011).
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module. We did not impose any language restrictions and we
sought translations for non-English language studies.
Electronic searches
We searched the Cochrane Stroke Group Trials Register (last
searched by the Managing Editor to May 2016), the Cochrane
Central Register of Controlled Trials (CENTRAL, Cochrane Li-
brary 2016, Issue 4; Appendix 1),MEDLINE (1946 toMay 2016;
Appendix 2), Embase (1974 toMay 2016; Appendix 3), CINAHL
(1937 to May 2016; Appendix 4), PsycINFO (1800 to Septem-
ber 2016; Appendix 5) and LLBA (1976 to November 2016;
Appendix 6) using comprehensive search strategies.
We searched major trials registers for ongoing trials including
the World Health Organization International Clinical Trials Reg-
istry Platform (who.int/ictrp/search/en/), the ISRCTN registry (
isrctn.com/), ClinicalTrials.gov (clinicaltrials.gov/) and the Stroke
Trials Registry (strokecenter.org/trials/).
Searching other resources
In an effort to identify other published, unpublished, and ongoing
trials we handsearched the reference lists of relevant articles and
contacted academic institutions and other researchers.
Data collection and analysis
Selection of studies
Our selection criteria were as follows.
• Research participants with dysarthria following stroke or
other adult-acquired, non-progressive brain injury.
• Interventions designed to reduce the dysarthria or its
impact on living with dysarthria.
• RCTs.
One author (CM) excluded any obviously irrelevant reports from
the titles and abstracts retrieved in the search. Three authors (CM,
AB, PC) independently examined the remaining abstracts and
then the full-text to determine eligibility and exclude irrelevant
reports. We resolved disagreements through discussion. No review
author examined their own study. We pursued finding confer-
ence proceedings and dissertations that were difficult to retrieve
using email contacts, university alumni societies, and conference
committees. We arranged for reports published in languages other
than English to be translated where required. Where possible, we
contacted authors of studies for clarification to inform discussions
around eligibility. All authors agreed final decisions on included
studies and proceeded to data collection. The studies we judged
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as ineligible for inclusion are listed with reasons for exclusion in
Characteristics of excluded studies.
Data extraction and management
Three authors (CM, AB, PC) independently carried out data ex-
traction from trial reports in pairs (avoiding authors’ own trials),
and extracted the following data.
• Methods: study design, study duration, sequence
generation, allocation sequence concealment, blinding.
• Participants: total number, attrition, setting, diagnostic
criteria, age, gender, country of research.
• Interventions: total number of intervention groups, specific
intervention and details.
• Outcomes: outcomes and time points, outcome definition
and measurement.
• Results: number of participants allocated to each
intervention, sample size, missing participants, summary data.
We attempted to contact trial authors for further information
where risk of bias was unclear or data were missing. We reconciled
the independent data extraction between pairs of review authors
and would have resolved any disagreements by discussion or with
reference to an independent arbitrator (ST) if required.
Assessment of risk of bias in included studies
Three authors (CM, AB, PC) independently carried out the as-
sessment of risk of bias and methodological quality within the
pairs assigned for data extraction. The authors used Cochrane’s
’Risk of bias’ tool (Higgins 2011).We examined the studies for the
following quality criteria: random sequence generation, allocation
concealment, blinding of outcome assessors, incomplete outcome
data, and selective reporting.
For random sequence generation (selection bias), we considered
trials to be low risk if the random component was clearly described,
at high risk of bias where randomisation was influenced by the
availability of the intervention, or an unclear risk where there
was insufficient information to decide. For allocation concealment
(selection bias), we considered trials adequately concealed if the
process made clear that participants and investigators could not
possibly predict allocation. We considered a study to be at high
risk if there was a possibility that allocation could be predicted
(e.g. open random allocation schedule, open computer systems
potentially accessible to the investigator), or where concealment
was unclear and the study author was unable to provide sufficient
information or did not respond.
It was accepted that the participants and the therapists delivering
the intervention could not be blinded to the intervention. Thus,
we considered blinding in terms of outcome assessment (perfor-
mance bias and detection bias) and we considered studies to be at
a low risk of bias if the outcome assessor was clearly blinded to the
intervention; we considered studies to be at a high risk of bias if
this was not the case, the blinding could be broken and an unclear
risk of bias if there was insufficient information provided.
We considered incomplete outcome data (attrition bias) a low risk
if there were:
• no missing outcome data;
• missing outcome data that were unlikely to be related to
true outcome;
• missing outcome data that were balanced in numbers across
intervention groups;
• similar reasons for missing data across groups; and
• missing data that had been imputed using appropriate
methods that did not affect outcome and were reported as such.
We considered studies to be at a high risk of bias if they did not
address:
• incomplete outcome data adequately;
• missing outcome data likely to be related to the true
outcome;
• imbalance of numbers or reasons for missing data across the
intervention groups;
• effect size among missing outcomes to induce clinically
relevant bias;
• an intention-to-treat analysis done with substantial
differences of the intervention received.
We considered selective reporting (reporting bias) within stud-
ies included in the review. We considered whether studies had
reported all outcome data compared with their planned proto-
cols (published or unpublished) where possible. Where this was
not possible, we asked study authors for additional information
on planned outcome reporting prior to the study. We considered
study authors who did not respond to this request an unclear risk.
Measures of treatment effect
We treated themeasures of functional speech as a continuous mea-
sure. We abstracted, calculated or requested means and standard
deviations. We calculated standardised mean differences (SMDs)
and confidence intervals (CIs), using a random-effects model for
the primary outcome and for any secondary outcomes measures
included.
Unit of analysis issues
For continuous data we requested or calculated the mean and
standard deviation (SD) data. We analysed outcomes as SMD and
95% CI. We used inverse variance and random-effects models.
We entered data so that a higher score represented a favourable
outcome.
We used RevMan 5 for all analyses (RevMan 2014).
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Dealing with missing data
We requested missing data from study authors as needed; this is
reported in Characteristics of included studies.
Assessment of heterogeneity
We assessed heterogeneity between trials with the selected compar-
isons and outcomes comparing measures, time points, trial design
and clinical subgroups. We determined statistical heterogeneity
based on the statistic with Chi² distribution. We quantified het-
erogeneity using the I² statistic, which describes the proportion of
total variance across trials. We considered heterogeneity of 40%
or more as considerable and 70% or more as substantial (Deeks
2011). Heterogeneity below 40% was considered low.
Assessment of reporting biases
We planned to explore reporting bias if 10 or more trials were
included in the review as outlined in The Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Data synthesis
The primary analysis pooled all trials in the meta-analysis, using a
random-effects model, including the dysarthria intervention ver-
sus any control (another intervention, attention control, placebo
or no intervention). We considered primary outcome data mea-
sures and secondary outcome measures at various time points (im-
mediate and persistent) and various levels of functioning.
GRADE and ’Summary of findings’ table
We created Summary of findings for the main comparison for the
main comparison and included the following outcomes:
1. dysarthria intervention versus any control: persisting effects,
activity level;
2. dysarthria intervention versus any control: persisting effects,
impairment level;
3. dysarthria intervention versus any control: persisting effects,
participation level;
4. dysarthria intervention versus any control for stroke
subgroup: persisting effects, activity level;
5. dysarthria intervention versus any control: immediate
effects, activity level; and
6. dysarthria intervention versus any control: immediate
effects, impairment level.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of the body of evidence as it related to the
included studies (Atkins 2004).We usedmethods and recommen-
dations described in Section 8.5 and Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
using GRADEproGDT software (GRADEproGDT 2015). We
justified all decisions to down- or upgrade the quality of studies in
footnotes, and provided comments to aid readers’ understanding
where necessary.
Subgroup analysis and investigation of heterogeneity
We carried out subgroup analysis to explore the effect of com-
parison with all controls (another intervention, attention control,
placebo or no intervention).We carried out clinical subgroup anal-
ysis of stroke or brain injury and a subgroup sensitivity analysis
where studies had low risk of bias.
Sensitivity analysis
We carried out sensitivity analysis to explore methodological het-
erogeneity including studies with adequate allocation concealment
and adequate blinding, these were the studies we considered to be
at low risk of bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies; and Characteristics of
studies awaiting classification.
Results of the search
Our searches identified 17,313 records; the screening process is
shown in the PRISMA flow diagram (Figure 1). Five papers met
our inclusion criteria (Bowen 2012; Kwon 2015;Mackenzie 2014;
Wenke 2010; Xu 2010) and are described in Characteristics of
included studies. We also identified two ongoing studies (Peng
2015; ReaDySpeech; see Characteristics of ongoing studies). Both
ReaDySpeech, and Peng 2015 presented insufficient detail to in-
form assessment, and will be assessed for inclusion in a future
review update. The study authors of Peng 2015 have been con-
tacted for further information; we will monitor for publication
of the study. You 2010 included an English language abstract,
but presents insufficient information to make a decision regard-
ing inclusion; this study is presented in Characteristics of studies
awaiting classification.
9Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram
Included studies
The included trials randomised a total of 234 participants, rang-
ing from 25 (Kwon 2015) to 66 (Bowen 2012). The five trials
are detailed in the Characteristics of included studies table and
we have included the comparison data below . All included stud-
ies were RCTs and each contributed to more than one compari-
son. We present data that compared one dysarthria intervention
with another dysarthria intervention and a dysarthria intervention
with an attention control. We found no studies that compared
dysarthria intervention with nothing or the same dysarthria in-
terventions with variations in timing, duration, or frequency of
delivery. Further information on intervention characteristics and
the main comparisons are presented in Characteristics of included
studies and Summary of findings for the main comparison.
The previous version of this review did not include any studies
(Sellars 2005).
Participant characteristics
All five included trials recruited men and women; the proportion
of men ranged from 56% (Bowen 2012) to 85% (Kwon 2015).
The average age ranged from 49 years (Wenke 2010) to 70 years
(Bowen 2012). Four studies included only people with stroke
(Bowen 2012; Kwon 2015;Mackenzie 2014; Xu 2010); one study
included people with stroke and a small number with traumatic
brain injury (Wenke 2010). Two studies tested interventions that
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were provided in the first four months (Bowen 2012) and two
months following stroke (Kwon 2015). Two studies involved par-
ticipants who were in the chronic stage of recovery (Mackenzie
2014; Wenke 2010). Xu 2010 included people between one and
12 months after stroke.
Participants were recruited from hospital (Bowen 2012; Xu 2010),
the community (Mackenzie 2014), or the source of recruitment lo-
cation was not specified (Wenke 2010) or not clear (Kwon 2015).
Three studies reported dysarthria severity assessed and reported
as part of study characteristics (Bowen 2012; Mackenzie 2014;
Wenke 2010). People with severe dysarthria were excluded in Xu
2010 and severity was not reported in Kwon 2015. Co-occurring
communication impairment or cognitive problems were excluded
by two studies (Kwon 2015;Xu 2010).Co-occurring aphasiaswere
described in Bowen 2012 andMackenzie 2014 but not mentioned
in Wenke 2010; however, Wenke 2010 identified co-existing cog-
nitive impairment. Bowen 2012 recruited people with commu-
nication difficulties after stroke including aphasia, dysarthria, or
both. People with dysarthria were a planned subgroup within the
study by Bowen 2012 and we extracted dysarthria data from the
trial data.
Intervention and control interventions
None of the included studies compared dysarthria interventions
with no intervention. Two trials compared an intervention with
an attention control (Bowen 2012; Kwon 2015). Bowen 2012
investigated enhanced best practice speech and language therapy
delivered by speech and language therapists supported by assis-
tants compared with an attention control (employees offering an
equivalent amount of time and social contact but no therapy or
therapist input). Kwon 2015 investigated repetitive transcranial
magnetic stimulation versus sham repetitive transcranial magnetic
stimulation; both groups received the same speech therapy inter-
vention.
Three trials compared dysarthria interventions with usual
dysarthria care (Mackenzie 2014; Wenke 2010; Xu 2010).
Mackenzie 2014 examined oro-motor exercises compared with
usual care. Wenke 2010 investigated Lee Silverman Voice Treat-
ment (LSVT), an approach that focusses on increased volume of
speech, with usual care. Xu 2010 compared acupuncture with
usual care. Usual care was described as behavioural strategies that
address impairment and activity levels of functioning (Mackenzie
2014; Wenke 2010; Xu 2010). Wenke 2010 andMackenzie 2014
reported that usual care was based on existing literature and best
practice guidelines; Wenke 2010 also included consensus agree-
ment. Components of usual care were not reported in Xu 2010.
There were no comparisons of one intervention versus the same
intervention with variations in timing, intensity, or duration of
treatment.
We referred to the template for intervention description and repli-
cation checklist (TiDier) when extracting the information on the
interventions for each study (Hoffmann 2014).
Intervention compared with attention control
Two studies assessed dysarthria interventions comparedwith atten-
tion controls (Bowen 2012; Kwon 2015; 86 participants). Bowen
2012 Investigated enhanced, flexible, best practice behavioural
speech therapy, and Kwon 2015 examined repetitive transcranial
magnetic stimulation. The enhanced, best practice intervention
in Bowen 2012 was described in sufficient detail to enable repli-
cation from the manual provided and was agreed by consensus
of speech and language therapists to address impairment, activity,
and participation levels of functioning. Kwon 2015 described the
repetitive transcranial magnetic stimulation intervention, equip-
ment used, and how motor-evoked potentials were calculated and
established for each participant. The intervention was to be led by
an experienced speech and language therapist in Bowen 2012, and
in Kwon 2015, the intervention was carried out by a physiatrist
(physicians specialising in physical medicine and rehabilitation).
The attention control applied inBowen 2012 was structured social
contact, carried out by employed, part-time, visitors; five of nine
visitors had high levels of educational attainment. In Kwon 2015
the attention control was sham repetitive transcranial magnetic
stimulation, carried out by the same physiatrist using the same
methods as the intervention, but holding the coil perpendicular
to the skull rather than tangential to the skull surface.
The population in both studies was people with stroke, both in-
terventions and attention control were delivered at the same time,
soon after stroke, within the first two months (Kwon 2015), and
within the first four months (Bowen 2012).
Repetitive transcranial magnetic stimulation treatment duration
was five days per week for two weeks (Kwon 2015). Enhanced
speech therapy was conducted for a maximum of 16 weeks, with
duration and frequency as clinically indicated up to a maximum
of three times per week (Bowen 2012). Bowen 2012 mentioned
homework, which was given as appropriate to people in the in-
tervention arm, but not to the attention control arm participants.
The unpublished intervention manual provided by the Bowen
2012 study authors, includes a sheet to encourage documentation
of homework by participants, but there is no further description
of whether homework was carried out or completed. Participants
in the intervention arm discussed homework and its impact dur-
ing interviews conducted as part of the qualitative aspect of this
study. Kwon 2015 describes that both groups had the same speech
therapy intervention carried out for 30minutes, five days per week
for the two weeks of rTMS treatment. The content of the speech
therapy interventionwas not described, although it was carried out
by a skilled speech therapist. There was no mention of homework
in Kwon 2015. Participants in the study by Kwon 2015 were not
aware of the intervention type they were randomised to receive
- either the active repetitive transcranial magnetic stimulation or
the attention control sham therapy.
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The outcome measure for Kwon 2015 was a blinded assessment
of impairment level immediately post intervention. Participants
in Bowen 2012 were aware of the intervention type they were ran-
domised to receive; the primary outcome was a blinded assessment
of activity level functioning at six months post-entry to the study.
Intervention A compared with intervention B
Three trials, involving a total of 117 randomised participants,
compared one intervention with another intervention (Mackenzie
2014; Wenke 2010; Xu 2010). All three studies compared usual
care versus an alternative intervention (Mackenzie 2014; Wenke
2010; Xu 2010). There were no trials that compared one inter-
vention with the same intervention but with variations in timing,
duration, or intensity of delivery.
InterventionA inWenke 2010 was Lee SilvermanVoice Treatment
(LSVT) which aims to increase vocal loudness. In Xu 2010, inter-
vention A was acupuncture; and in Mackenzie 2014 10 minutes
of non-speech oro-motor exercises (tongue and lip movements)
replaced 10 minutes word and sentence practice.
Intervention A was delivered by the same speech pathologist
trained in LSVT inWenke 2010; traditional Chinese medical spe-
cialists carried out acupuncture in Xu 2010; and the same ex-
perienced speech and language therapist provided treatment in
Mackenzie 2014.
Intervention B in all three studies was usual care.
Wenke 2010 and Mackenzie 2014 described intervention B as
behavioural therapy, addressing impairment and activity levels of
functioning. Both studies provided sufficient information to en-
able replication of the therapy. Xu 2010, did not describe inter-
vention B in sufficient detail to enable replication; there was no
information around the content of the therapy, level of impair-
ment, or how therapy was delivered.
Intervention B was delivered by an experienced speech pathologist
in Wenke 2010; the same hearing and speech specialist delivered
the usual care to participants in both arms in Xu 2010; and the
same experienced speech and language therapist delivered both
intervention A and B in Mackenzie 2014.
Treatment timing was for people in the chronic phase of recovery
following stroke or brain injury of more than six months or more
than three months in Wenke 2010 and Mackenzie 2014 respec-
tively. In Xu 2010 timing ranged for people with acute to chronic
dysarthria of between one and 12 months post stroke.
Treatment duration ranged from four weeks (Wenke 2010), to
eight weeks (Mackenzie 2014) and nine weeks (Xu 2010).
Treatment frequency for interventions A and B was the same for
Wenke 2010, at one hour per day, four days a week, and the same
for Mackenzie 2014 at 40 minutes once a week. Xu 2010 differed,
with both arms receiving speech therapy for 30 minutes, five times
per week but intervention A was delivered for four weeks, with a
week long break followed by four weeks of intervention A.
Independent practice of homework was described inWenke 2010
and Mackenzie 2014 but was not used in Xu 2010. In Wenke
2010, independent, daily homework was suggested between ses-
sions for intervention B group participants only, but whether this
was carried out and recorded was not described. In Mackenzie
2014, participants in both intervention A and B were encouraged
to carry out independent practice of their allocated intervention
of around 30 minutes, five days a week during the seven between
session practice weeks for a total of 1050 minutes. This was doc-
umented by participants in a diary and the results reported and
analysed.
All participants in the three studies were aware of which inter-
vention they were randomised to, none of the three studies had a
primary outcome measure.
All three studies carried out an activity level measure, with this
being considered to show persistent change for Wenke 2010 at
six months post treatment, and Mackenzie 2014 at two months
post intervention in a chronic population, but was only carried
out immediately post intervention in Xu 2010.
Outcomes
All five studies used different outcome measures and at various
time points. The primary outcome for this review was to examine
the persisting effect of the intervention at the activity level of
functioning.
Four studies carried out activity level measures (Bowen 2012;
Mackenzie 2014; Wenke 2010; Xu 2010). Kwon 2015 did not
carry out a measure of activity level of functioning.
Wenke 2010 and Xu 2010 used a measure of perceived intelli-
gibility by a speech and language therapist, Bowen 2012 used
the dysarthria therapy outcome measures (Enderby 1997), and
Mackenzie 2014 used the communication effectiveness measure
(Mackenzie 2007) and the Speech Intelligibility Test (Yorkston
1996). The only study that specified the primary outcome mea-
sure was Bowen 2012.
For our analyses of persisting outcome, we took data from mea-
sures carried out at three to nine months post intervention; this
included Wenke 2010 (six months post treatment) and Bowen
2012 (measured at six months post randomisation). Mackenzie
2014 carried out the final outcome measure at two months (eight
weeks) post intervention. The review authors discussed if these
data should be included, because this was a chronic population
with proximity to the proposed minimum time point of three
months (12 weeks). We decided that the proposed time criterion
(three months to nine months) in the review protocol was too
tight, and agreed to relax timings to include the study data as a
persisting effect. This change is reported in Differences between
protocol and review. The latest time point for the primary out-
come measure, taken by Xu 2010, was immediately post interven-
tion, which did not meet our requirement of three to nine months
post intervention to examine persistent change.
The secondary outcomes were other measures at various time
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points. This meant we examined data from the activity level mea-
sures at immediate time point post-intervention, and this had been
carried out by Wenke 2010, Xu 2010 and Mackenzie 2014. We
considered ’immediate’ measure to have been carried out at the
end of the treatment period or the time period nearest to the end
of treatment.
Communication impairment measures were used in four studies
(Kwon 2015; Mackenzie 2014; Wenke 2010; Xu 2010). These
were articulatory precision (Wenke 2010), maximum phonation
time (Xu 2010), lip and tongue movements from the Frenchay
dysarthria assessment (FDA-2) (Mackenzie 2014), and an articu-
lation test (Kwon 2015). These impairment measures were carried
out to show persistent effect between the three month and nine
month time points by Wenke 2010 and Mackenzie 2014, but not
Xu 2010 or Kwon 2015. These measures were carried out immedi-
ately post-intervention by all four studies (Kwon 2015;Mackenzie
2014; Wenke 2010; Xu 2010). Measures at the participation level
were used by Bowen 2012, which used the Communication Out-
comes after Stroke Scale (COAST; Long 2008), and Mackenzie
2014, which used the Communicative Effectiveness Survey (CES;
Donovan 2007). Both studies applied this participation levelmea-
sure as a persistent measure of change between three month and
nine months, but only Mackenzie 2014 applied this immediately
post treatment.
Excluded studies
See: Characteristics of excluded studies
We excluded 28 studies primarily because they were not RCTs
(Fitzgerald-DeJean 2008; Fukusako 1989; Garcia 1998; Huffman
1978; Huh 2014; Hustad 2003; Ince 1973; Jones 1972; Kati
1973; Li 2013; Markov 1973; Nagasawa 1970; Palmer 2004;
Palmer 2007; Robertson 2001; Rosenbek 2006; Sakharov 2013;
Togher 2014; Varma 2004). In several studies, participants were
not dysarthric (Behn 2011; Behn 2012; Braverman 1999; Sze
2002; Togher 2004), or had mixed aetiologies including progres-
sive and congenital conditions (Cohen 1993; Kelly 2000; Main
1998), or a surgical intervention was investigated (Qinglan 2002).
Risk of bias in included studies
Overall risk of bias for the five included studies is depicted in
Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Three review authors independently assessed the included stud-
ies for methodological quality (avoiding their own studies) and
discussed any discrepancies. We intended to carry out sensitivity
analysis according to studies at low risk of bias for each domain.
We considered that two studies were at low risk of bias overall,
and these were included in the sensitivity analysis (Bowen 2012;
Mackenzie 2014). All five included studies reported inclusion and
exclusion criteria.
Allocation
We assessed twoRCTs at low risk of bias for both random sequence
generation and allocation concealment (Bowen 2012; Mackenzie
2014). One study, while demonstrating random sequence gener-
ation, provided insufficient details to determine adequacy of al-
location concealment (Wenke 2010). Two studies provided in-
sufficient details around random sequence generation and alloca-
tion concealment and we considered them to have unclear risk
of bias without further clarification (Kwon 2015; Xu 2010). All
included studies demonstrated adequate matching between ran-
domised groups at baseline with no obvious concerns around risk
in this area.
Blinding
Blinded outcome assessment on all measures was clearly described
by Bowen 2012 and Mackenzie 2014. It is not clear in Wenke
2010, Xu 2010 or Kwon 2015 whether those involved in the
outcome assessments were blind to the intervention. Although it
was implied that those carrying out the outcome measures were
not involved in the study, reporting was not sufficiently clear for
this to be assessed as low risk without further information and
evidence that the blinding process was not easy to break.
Incomplete outcome data
Not all studies described completion of intervention, those that
did reported a total of 14 (from 112 randomised participants)
withdrawals, with no differences between intervention and control
group participants (Bowen 2012; Kwon 2015; Mackenzie 2014).
All five studies reported the number of participants lost to some
or all of the follow-up assessments and across all five studies 33
out of the 234 randomised had either no follow up assessment or
incomplete follow up assessment. We considered Xu 2010 to be at
low risk of bias; there was no attrition from recruitment to follow-
up. Bowen 2012 was assessed as low risk of bias for incomplete
data; detailed explanations were provided in the study’s data anal-
ysis. Missing data from Mackenzie 2014 was discussed with the
study authors, who provided additional information about their
analysis using imputed results andmultiple imputations hadmade
no difference to the findings; we rated this study as low risk of
bias. Wenke 2010 reported treating missing data in a standard
statistical way; however, implications were not fully addressed and
without further information, this study was assessed at high risk
of bias. Reporting in Kwon 2015 raised significant concerns about
incomplete outcome data: five participants were randomised to
both treatment arms, but three withdrew from the active treatment
arm and two from the sham treatment. Data for these participants
were withdrawn from the study; no intention-to-treat analysis was
carried out or discussion included around the implications of these
withdrawn data on conclusions. We assessed Kwon 2015 at high
risk of bias for this domain.
Adherence to intervention and dropout rates by included study
are described in Characteristics of included studies.
Selective reporting
Bowen 2012, Mackenzie 2014 and Wenke 2010 reported studies
in full with specified outcome measures at specified time points.
Bowen 2012 also published a protocol and analyses.
Possible presence of selective reporting was harder to ascertain for
Xu 2010 and Kwon 2015. Both studies were assessed at unclear
risk of bias for selective reporting. This assessment will be revised
following confirmation of methods applied and clarification from
the study authors.
Effects of interventions
See: Summary of findings for the main comparisonDysarthria
intervention compared with another intervention, attention
control, placebo or no intervention for people with dysarthria after
stroke or other adult-acquired, non-progressive brain injury
See: Summary of findings for the main comparison
The results of this review are presented below to show the evi-
dence for the objectives of the review. The main objective was to
find whether there was an effect on dysarthric speech of any in-
tervention and this is presented below under the three compar-
isons. In summary there was no evidence of a long-term effect of
the dysarthria intervention on everyday speech compared to any
control.
Results are described for comparisons in each outcome.
• Dysarthria intervention compared with another
intervention, attention control, placebo or no intervention:
persisting effects.
• Dysarthria Intervention compared with another
intervention, attention control, placebo or no intervention:
immediate effects.
• Dysarthria intervention A versus dysarthria intervention B
(whether this is two different interventions or the same
intervention with varying timing, duration, and frequency of
delivery): persisting and immediate effects.
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We included five studies that involved a total of 234 randomised
participants. Comparisonswere analysed according to our primary
outcome of persisting effects of communication at activity level
(three RCTs, 116 participants). Comparisons were further anal-
ysed for measurement of impairment and participation at imme-
diate and persistent time points. Data were also considered for
one subgroup of people with stroke because there were insufficient
data for any other clinical subgroups.
We calculated standardised mean difference (SMD) and 95% con-
fidence intervals (CI) because different measures were used of the
same underlying construct. We used a random-effects model.
Comparison 1: dysarthria intervention versus any
control: persisting effects (three to nine months post
intervention), activity level
We found no evidence of an effect for persisting effects at commu-
nication activity level for any control (Bowen 2012; Mackenzie
2014;Wenke 2010; 116 participants): SMD 0.18, (95% CI -0.18
to 0.55, Tau² = 0.00; Chi² = 1.47, df = 2, P = 0.48; I² = 0%;
GRADE: low quality). Findings were very similar for each study,
with narrow CIs, but very small numbers of participants. None
of the studies were adequately powered to find an effect (Analysis
1.1). We considered two of the three studies to be at low risk of
bias.
Secondary outcomes of dysarthria intervention versus any
control: persisting effects (three to nine months),
impairment or participation level
We found no evidence of a persisting effect on impairment level
measures in favour of any treatment (Mackenzie 2014; Wenke
2010; 56 participants, SMD 0.07, 95% CI -0.91 to 1.06; Tau² =
0.35; Chi² = 3.32, df = 1 (P = 0.07); I² = 70%; GRADE: very low
quality). There was substantial heterogeneity between the trials
(Analysis 1.2). Both studies had small numbers of participants,
and neither study was adequately powered. We considered one
study at low risk of bias.
These two RCTs (79 participants) found no evidence of a per-
sisting effect at the participation level (Bowen 2012; Mackenzie
2014): SMD -0.11 (95% CI -0.56 to 0.33) and Heterogeneity:
Tau² = 0.00; Chi² = 0.16, df = 1 (P = 0.69); I² = 0%; GRADE:
low quality (Analysis 1.3). These two studies have small numbers,
they are not adequately powered, and only one has a low risk of
bias.
Sensitivity analysis of dysarthria intervention versus any control
(persisting effects, activity level) included two studies with ad-
equate allocation concealment/adequate blinding (Bowen 2012;
Mackenzie 2014). The data from the sensitivity analysis of these
two studies with 92 participants showed no effect and slight het-
erogeneity (SMD0.21, 95%CI -0.30 to 0.73, heterogeneity: Tau²
= 0.05; Chi² = 1.47, df = 1 (P = 0.23); I² = 32%; GRADE: low
quality) (Analysis 1.4).
Only one of the studies had a comparison of dysarthria interven-
tion versus attention control with a measure of persisting effects
at the activity level. This one study with 60 participants (SMD
0.00, 95% CI -0.51 to 0.51), indicated no evidence of an ef-
fect when comparing the intervention with an attention control
(Bowen 2012) (Analysis 1.5).
The stroke subgroup for comparison 1 included three studies (
Bowen 2012; Mackenzie 2014; Wenke 2010; 106 participants)
and showed no evidence of effect (SMD 0.16, 95% CI -0.23 to
0.54, Chi² = 1.61, df = 2, P = 0.45; I² = 0%; GRADE: low quality;
Analysis 1.6).
Comparison 2: dysarthria intervention compared
with another intervention, attention control, placebo
or no intervention: immediate effects at activity,
impairment and participation level
Three included studies, with 117 participants, had measures of
activity level immediately post intervention but found no evidence
of an effect: (SMD0.29, 95%CI -0.07 to 0.66) (Mackenzie 2014;
Wenke 2010; Xu 2010). The heterogeneity among studies was low
but included very small numbers (Chi² = 0.64, df = 2 (P = 0.73);
I² = 0%) GRADE: very low quality) (Analysis 2.1).
Four studies measured impairment level immediately post inter-
vention (Kwon 2015; Mackenzie 2014; Wenke 2010; Xu 2010).
These studies had a total of 99 participants, so each included small
numbers of participants but there was a statistically significant ef-
fect favouring intervention (P value = 0.04), SMD 0.47 (95% CI
0.02 to 0.92) with low heterogeneity (Chi² = 0.73, df = 2 (P =
0.69); I² = 0%). Only one study was low risk of bias, GRADE:
very low quality (Analysis 2.2).
One study measured participation level immediately post inter-
vention (Mackenzie 2014). This single study had 32 participants:
SMD -0.24 (95% CI -0.94 to 0.45) indicating no effect of the
intervention (Analysis 2.3).
Comparison 3: dysarthria intervention A versus
dysarthria intervention B: persisting and immediate
effects at activity, impairment and participation level
Due to the small number of studies in this review there are only two
comparisons in this section that have not already been carried out
in the earlier analysis. It may be possible to populate this section
more fully in the future as more trials are carried out.
Analysis 3.1 included two studies of 56 participants comparing
intervention A versus B, with a measure of persisting effects at
the activity level: SMD 0.38 (95% CI -0.15 to 0.91) indicating
no effect of intervention (Mackenzie 2014; Wenke 2010). These
studies have low heterogeneity (Heterogeneity: Tau² = 0.00; Chi²
= 0.43, df = 1 (P = 0.51); I² = 0%; GRADE: very low quality).
The second analysis of intervention A versus intervention B that
has ameasure of persisting effect at the participation level included
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one study: Mackenzie 2014. This study has 32 participants: SMD
-0.22 (95% CI -0.92 to 0.47) and indicates no effect of the inter-
vention (Analysis 3.2).
We would also have carried out analysis on intervention A versus
intervention B, persisting effects at the impairment level but this
has been carried out in Analysis 1.2.
We would have looked at intervention A versus intervention B,
immediate effects; activity level (Analysis 2.1), impairment level
(Analysis 2.2), participation level (Analysis 2.3) but these have
already been carried out in the earlier comparisons.
D I S C U S S I O N
We examined the effectiveness of dysarthria interventions for peo-
ple with speech problems due to stroke and other adult-acquired,
non-progressive brain injury. We have built on the work of Sellars
2005 presented in the previous version of this review, by amend-
ing and updating objectives and review outcomes to reflect a more
global perspective, and to consider new evidence. We considered
whether dysarthria interventions were effective when compared
with any control, whether the dysarthria intervention was more
effective than an attention control, whether one type of dysarthria
intervention was more effective than another, or whether one type
of dysarthria intervention was more effective than the same inter-
vention when delivered in a different way.We included five studies
and presented data from 234 randomised participants.
Summary of main results
See: Summary of findings for themain comparison.Meta-analyses
demonstrated no evidence of a statistically significant persisting
effect of dysarthria intervention compared with any control when
communication was measured at either the activity (three studies,
116 participants), impairment (two studies, 56 participants), or
participation level (two studies, 79 participants). This lack of effect
did not change in the sensitivity analyses of only the studies with
a low risk of bias (two studies, 92 participants), when the analy-
sis was restricted to those with an attention control/placebo (one
study, 60 participants), or to the subgroup of those with an un-
derlying condition of stroke (three trials, 106 participants). Simi-
larly, there was no evidence for the immediate effect of dysarthria
intervention at the activity level (three studies, 117 participants)
or participation level (one study, 32 participants). The one signif-
icant finding at the impairment level immediately post-interven-
tion, (four trials, 99 participants) means that clinically there may
be some improvement of tongue and lip movement for example
but there is no evidence that these persist long-term and the very
small numbers and very low quality of the evidence make this an
uncertain estimate.
Key findings from this review
• Despite one positive finding, there was insufficient evidence
to enable firm conclusions to be drawn due to quality of the
evidence.
• Evidence quality was graded as low or very low.
• There was low risk of bias in only two studies.
• There was no consensus on outcome measures or time
points for measurement.
Overall completeness and applicability of
evidence
We only identified five, small trials which indicates the evidence
base is limited. In addition to the limited number of trials there
were only small numbers of participants within the trials and there
were also issues around quality and risk of bias. There is clearly
much more that needs to be done before the objectives of the re-
view canbe fully addressed.Thewide variety of outcomemeasures,
where none of the five trials used any of the same outcome mea-
sures, indicates a need for consensus amongst researchers, people
with dysarthria and clinicians to identify which measures should
be used in future research. However the included studies were
all relevant to the review question in that they were all RCTs of
dysarthria intervention for stroke and brain injury. The review set
out to establish the evidence for all clinical groups who may have
dysarthria but we found no RCTs for other types of non-progres-
sive brain injury that may cause dysarthria. One of the studies ex-
cluded people with severe dysarthria and one did not report sever-
ity so generalisation to the wider dysarthric population could be
affected.
There were variable amounts of information relating to inter-
vention and control description and replicability according to
the TIDieR checklist that we used when evaluating the studies
(Hoffmann 2014). In two of the studies this was clearly described
in sufficient detail for replication (Bowen 2012;Mackenzie 2014).
There was less detail in Wenke 2010, although the LSVT inter-
vention used in this study cannot be described as the treatment
is trademarked and not available publicly. Xu 2010 gave minimal
information about the usual care interventions in both arms, and
this could not be replicated from the information given but they
provided much more detail about the acupuncture delivery. Kwon
2015 gave detail around the transcranial magnetic stimulation in-
tervention and how the sham/attention control was carried out.
There was no detail around the speech therapy that was given to
both groups to ensure they had the same treatment alongside the
transcranial magnetic stimulation intervention and sham. There
was variation in reporting whether the intervention was provided
as intended by the protocol and this is detailed in Characteristics
of included studies . Fidelity of the intervention and how this
was monitored was not described in Wenke 2010, Xu 2010 or
Kwon 2015 which is important when considering applicability of
the evidence. Fidelity to the interventions and attention control
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was described in detail, including information about how this was
monitored, who carried this out, when and how, in Bowen 2012
and Mackenzie 2014. Whether participants completed the inter-
vention in the arm to which they were allocated was described in
Bowen 2012 and Mackenzie 2014. Current practice in the UK
around rehabilitation continues to focus on early intervention and
the review included three studies of early intervention whereas the
other two considered intervention with a chronic population.
Quality of the evidence
This review shows that we do not have a robust enough body
of evidence to draw firm conclusions about the objectives of this
review. It is ameasure of progress that there were recent studies that
could be included in the meta-analyses however we rated evidence
quality for the key outcomes as low or very low (Summary of
findings for the main comparison). The primary objective of this
review was reported by only three of the studies (116 participants;
Analysis 1.1). However, none of the three studies were adequately
powered to enable comparisons of the interventions because of
the small numbers of participants. Bowen 2012, while adequately
powered to look at early communication intervention in aphasia
and dysarthria, was not adequately powered to evaluate dysarthria
intervention only. All secondary outcomes were downgraded due
to small participant numbers and imprecision.
Only Bowen 2012 and Mackenzie 2014 had low risk of bias;
the other three studies all had areas of unclear risk or high risk.
We carried out sensitivity analyses to remove any studies with
high or unclear risk of bias but this did not alter the direction or
the significance of the results (Analysis 1.4). The one significant
finding was from four studies where we considered the overall
quality of the evidence to be very low,which raises concerns around
how confident we can feel about this estimate of effect (Analysis
2.2). The main message about the quality of the evidence found
in this review is that, in addition to being adequately powered,
the reporting of RCTs must adhere to the CONSORT guidelines
(Schulz 2010) and follow the template for intervention description
and replication (TIDieR; Hoffmann 2014).
Potential biases in the review process
The search strategy was broadened for this review to include tri-
als that may have been carried out by a range of professionals or
non-professionals and we felt confident that we used search terms
to reflect this broad scope. However, not knowing what poten-
tial professional or non-professional groups may be carrying out
research may introduce the possibility of bias particularly where
unpublished literature or ongoing trials were sought, as only those
who have worked or are working in the field of dysarthria were
approached.
The search strategy was in line with this broad approach and we
documented reasons for study exclusions. We carried out searches
with no time restrictions: the searches were all carried out in En-
glish language databases, and althoughwe imposed no language re-
strictions, and had a paper published in Chinese (Xu 2010) trans-
lated, this may have restricted our searchmethod. It is highly prob-
able that papers published in other languages were not identified,
and this review may be biased toward English-speaking research
studies. Xu 2010 was published inChinese and data extraction was
carried out by two independent Chinese-speaking individuals, but
neither were involved in the review team; discrepancies with data
extraction may have occurred. There was some need for interpre-
tation of information, which may not be entirely as intended by
the author. Where clarification could not be obtained from study
authors, it is possible that information may have been interpreted
incorrectly, and that the review is biased until information can be
clarified.
Data collection was carried out by individual review authors and
then compared in an attempt to reduce any bias around particular
methodologies or intervention approaches. To ensure risk of bias
judgements were carried out fairly this was considered indepen-
dently and then compared and discussed by the review team.
The review team was conscious that a review author (AB) was also
the lead author of an included study. We considered how to ap-
proach this before starting the review, should the study be eligi-
ble for inclusion. The review was structured to ensure the study
author was not involved in assessing or making judgements about
her own study. However, AB provided additional information and
data when requested, and contributed her opinion to wider dis-
cussions where this was relevant. We were very conscious of the
potential for bias in this particular situation and took steps to re-
duce bias as much as possible.
Agreements and disagreements with other
studies or reviews
A previous Cochrane review of dysarthria intervention found no
suitable studies for inclusion at that time (Sellars 2005). There are
no other systematic reviews of non-progressive dysarthria.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Research evidence is not yet sufficiently robust to guide clinical
practice. It is therefore important for clinicians to continue to
offer rehabilitation for people with dysarthria in line with current
clinical guidelines.
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Implications for research
Further research will need to be appropriately designed to avoid
risk of bias, and evaluate persisting effects on activity level mea-
sures.
The absence of evidence for dysarthria interventions highlights
the paucity of research for this distressing condition, and need for
adequately-powered, methodologically-sound and well-reported
studies.
Although inclusion of five studies (from none 10 years ago) is to
be celebrated, much more needs to be done. Dysarthria research
activity is in striking contrast to aphasia research, which has now
amassed 57 trials of speech and language therapy interventions for
aphasia following stroke (Brady 2016).
Future dysarthria trials should clearly report methods governing
randomisation, allocation concealment, clarity around attrition,
and include evidence of full reporting of all outcomes. Where pos-
sible, blinding of outcome assessment is desirable, but is not always
possible to achieve in rehabilitation research. When considering
methodological approaches, researchers may want to consider a
range of control groups such as comparing interventions with no
treatment, or alternative treatment, or an attention control. These
control arms answer different but important questions.
It is important to consider follow-up and intention-to-treat anal-
ysis: these are important factors in minimising bias.
Rehabilitation trialists will find it helpful to adhere to the CON-
SORTguidelines for all future studies. Future definitive trialsmust
have adequate statistical power to detect clinically meaningful dif-
ferences and this may be informed by feasibility and pilot trials.
It would be helpful if researchers could agree core outcome sets and
timing of measurements. Interventions should be clearly described
and replicable, and researchers would benefit from adherence to
the TIDieR checklist.
Future studies should include patients’ and carers’ views on the
available interventions and the most meaningful way of measur-
ing treatment effects. Patients’ and carers’ views on acceptability
of available interventions and acceptability measures (adherence
or satisfaction scales) should be considered in future studies. The
involvement of patients and carers in commissioning and design-
ing research would greatly increase the quality of the research dis-
cussion especially related to potential interventions and possible
outcome measures. We found no studies considering timing, in-
tensity, and duration of interventions, which are concepts of clin-
ical importance that need to be considered in future research.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
Bowen 2012
Methods Study design: RCT
Study duration: December 2006 to end of follow up July 2010
Pragmatic, parallel, superiority RCT with blinded outcome assessment
This was a larger trial of all communication impairments following stroke and the
dysarthria population was a planned subgroup from this larger trial. We were able to
extract the data for the dysarthria population
Participants Inclusion criteria
• Setting: hospital, multicentre, North West England
• Country: England
• Health status: people with stroke and communication impaired due to aphasia or
dysarthria; considered, by the speech and language therapist, able to engage in therapy;
considered, by the speech and language therapist, likely to benefit from
communication therapy; informed consent or proxy consent provided by carers
• Number: 66 participants with dysarthria randomised (from the larger trial of
participants with aphasia and/or dysarthria = 170); treatment (n = 34); control (n = 32)
• Age: (mean, SD)
◦ treatment: 70 ± 11.4
◦ control: 67 ± 11.8
• Sex (M/F): treatment (n = 27/7); control (n = 20/12)
• Time post stroke/brain injury: this was a trial of early intervention so participants
were within the first four months post stroke: both groups median time from stroke to
randomisation: 12 days
• Severity of dysarthria: 53% severe dysarthria, both groups
• Other communication impairment: intervention: 25/34 had aphasia; attention
control: 24/32 had aphasia
Exclusion criteria
• subarachnoid haemorrhage; dementia; pre-existing learning disabilities likely to
prevent benefit from therapy; unable to communicate in the English language; other
serious concomitant medication conditions; patient unable to complete eligibility
screening after 3 attempts over 2-week period; family or carer objections; case when a
speech and language therapist was asked to contribute to an urgent assessment of a
person’s mental capacity to consent to an NHS treatment, before the therapist had time
to complete screening to determine eligibility for the trial
Interventions Treatment group
• Intervention: intervention was multifaceted and tailored to individual needs, but
consisted of 6 core components
◦ assessment & information gathering, using standardised methods
◦ information provision regarding communication difficulties, intervention
goals, progress, etc
◦ communication materials to record interventions & activities, plus provision
of AAC devices as appropriate
◦ information and training for carers
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Bowen 2012 (Continued)
◦ indirect contact with MDT colleagues regarding patient needs
◦ one-to-one contact involving intervention for speech and language
impairment, psychosocial impacts, activities, etc, as appropriate to the individual
dysarthria
◦ intervention delivered was classified according to impairment type
including: impairment (97%), activity (61%), participation (61%)
• Start of treatment: intervention started approximately 2 weeks after admission to
hospital and before 16 weeks
• Duration: lasted a maximum of 16 weeks with three contacts per week - but this
was variable
• frequency: participants were seen up to 3 times per week for a maximum of 4
months, as required mean 15 hours, 20 contacts
• administration: participants were seen by a highly qualified speech and language
therapist intervention was designed, implemented and monitored by qualified SLT,
employed by NHS trusts. SLTs delivered most of the one-to-one contacts but some
were delivered by supervised assistants. 43% contacts experienced therapist, 54%
contacts less experienced therapist
• Fidelity: direct monitoring of therapy sessions, case notes, goal setting audit by
experienced therapist involved in study
• Location: intervention took place in a number of settings as appropriate to the
participant’s care pathway
• Adherence: 33/34 completed
• Homework: advised to carry this out as frequently as possible no data on this
Attention Control group
• Intervention: intervention started approximately 2 weeks after admission to
hospital. Sessions consisted of 3 stages:
• ◦ building rapport and getting to know each other, finding common ground
◦ regular contact sessions including general conversation and activities
◦ winding down sessions
• Duration: lasted a maximum of 16 weeks with 3 contacts per week - but this was
variable
• Frequency: sessions were 60 minutes maximum duration and tailored to
individual needs, with activities being participant-led. 15 hours, 19 contacts
• Administration: employed, part-time visitors employed to carry out structured
social contact with high level educational attainment, planned and implemented by
part time staff employed for the study, with no prior experience or specific training in
stroke rehabilitation
• Fidelity: monitor-trained visitors, supervised and monitored sessions according to
protocol
• Location: intervention took place in a number of settings as appropriate to the
participant’s care pathway
• Adherence: attention control: 27/32 completed
• Homework: none for control group
Outcomes Outcomes used in this review:
• Primary outcome measure: Therapy Outcome Measure (TOM) activity sub scale
Secondary outcomes:
• participants’ perception on the Communication Outcomes After Stroke scale
(COAST)
25Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bowen 2012 (Continued)
• carer’s perceptions of participants from part of the Care COAST
• carer wellbeing on Carers of Older People in Europe Index
• quality of life items from Carer COAST
• serious adverse events
• economic evaluation
• participants’ utility (European Quality of LIfe-5 Dimensions, EQ-5D)
Methods to measure outcomes: Primary outcome: blinded, functional communicative
ability assessed on the TOM activity sub scale. A conversation with an unfamiliar con-
versation partner was rated using the TOM by an expert independent expert speech and
language therapist
Outcomes were evaluated at baseline and 6 months post randomisation, with 2-month
gap between completion of intervention and final assessment
Numbers lost to follow up: intervention lost 4/34; attention control lost 8/32
Notes Funding source: this project was funded by the NIHR Health Technology Assessment
programme. The Stroke Association funded part of the excess treatment costs
Contact with study authors for additional information: primary outcome reported for
subgroups of diagnosis (i.e. aphasia, dysarthria); secondary outcomes not reported sepa-
rately Contacted the statistician involved in this paper for the dysarthria specific data of
all outcomes; this was provided in full
Other: we have ensured AB, author of this trial and involved in this Cochrane review,
has had no involvement in the review of this study but she contributed her opinion and
provided additional information when requested
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by an external, indepen-
dent, web-based randomisation service us-
ing a computer-generated string of ran-
dom permuted blocks. Participants were
randomised using a 1:1 allocation ratio in
blocks of 2, 4, and 6 with different com-
binations depending on site and stratified
according to severity and study centre
Allocation concealment (selection bias) Low risk External, independent, web-based
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment carried out by an in-
dependent speech and language therapist,
blinded to treatment allocation and not in-
volved in treating study participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT used and dropouts specified in report
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Selective reporting (reporting bias) Low risk Study protocol available and all statistical
data included in the report
Kwon 2015
Methods Study design: RCT: single centre, prospective, randomised, double-blind, sham stimu-
lation-controlled trial
Study duration: June 2013 to April 2015
Participants Inclusion criteria
• Setting: Department of Rehabilitation Medicine
• Country: Korea
• Health status: first-ever unilateral middle cerebral artery infarction
• Number: 25 post-stroke patients were therefore recruited and randomised into
the 2 study groups. A final total of 20 of these participants completed the study
• Age (mean, SD): intervention: 69.4 ± 11.8; attention control: 68.8 ± 9.8
• Sex (M/F): intervention: 10/0; attention control: 7/3
• Time post stroke/brain injury: duration from stroke onset ranged from 1 week to
2 months but all had experienced their first-ever stroke
◦ intervention in days: 26.4 ± 15.0
◦ attention control in days: 26.5 ± 12.7
• Severity of dysarthria: not reported
• Other communication impairment: excluded from study if any other impairment
communication or cognition
Exclusion criteria
• A total of 42 participants were initially enrolled in this study, but 17 were
excluded after being assessed for eligibility. Among the excluded patients, 11 did not
meet the inclusion criteria and 6 refused to participate
• Cognitive and speech function and those who had aphasia, apraxia of speech,
cognitive impairment (Mini Mental State Examination < 20), poor mental status, vocal
cord palsy, history of epilepsy, or bilateral infarction were excluded
Interventions Treatment group
• Intervention:
◦ this procedure was carried out as part of the intervention to establish motor-
evoked potentials. To determine the resting motor threshold and stimulation area,
motor-evoked potentials were recorded from the orbicularis oris muscles on each
participant’s non-affected side using transcranial magnetic stimulation. Focal
transcranial magnetic stimulation was applied using a Magstim Rapid magnetic
stimulator (Magstim Company Ltd, Dyfed, UK). Briefly, a Magstim circular coil
(external diameter, 90 mm) was placed onto each participant’s contralateral motor
cortex to identify the hotspot, defined as the area that produced the largest amplitude
of motor-evoked potentials. The resting motor threshold was defined as the stimulus
intensity required to produce motor-evoked potentials > 100 kV at a peak-to-peak
amplitude during 3 of 5 consecutive trials on the orbicularis oris
◦ the experimental intervention was LF stimulation, which involved being
seated in a comfortable chair with foam ear plugs, each participant was treated with 10
consecutive sessions (5 times per week for 2 weeks) of repetitive transcranial magnetic
27Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kwon 2015 (Continued)
stimulation, performed by a physiatrist who used a 70 mm, air cooled, figure-of-eight
Y-shaped coil. Repetitive transcranial magnetic stimulation was performed at a low
frequency (1 Hz), at 90% amplitude of evoked motor threshold, and with 1,500
stimulations/day on the hotspot
◦ this group also received speech therapy for 30 minutes, 5 days per week from
a skilled speech therapist who was blind to the nature of the study during the 2-week
intervention period
• Start of treatment: between 1 week and 2 months
• Duration: 2 weeks
• Frequency: 30 minutes, 5 days/week
• administration: physiatrist
• Fidelity: not described
• Location: Department of Rehabilitation Medicine
• Adherence: 3 participants were unable to complete the study in the repetitive
transcranial magnetic stimulation (10 completed)
• Homework: none
Control group
• Intervention:
◦ this procedure was carried out as part of the intervention to establish motor-
evoked potentials. To determine the resting motor threshold and stimulation area,
motor-evoked potentials were recorded from the orbicularis oris muscles on each
participant’s non-affected side using transcranial magnetic stimulation. Focal
transcranial magnetic stimulation was applied using a Magstim Rapid magnetic
stimulator (Magstim Company Ltd, Dyfed, UK). Briefly, a Magstim circular coil
(external diameter, 90 mm) was placed onto each participant’s contralateral motor
cortex to identify the hotspot, defined as the area that produced the largest amplitude
of motor-evoked potentials. The resting motor threshold was defined as the stimulus
intensity required to produce motor-evoked potentials > 100 kV at a peak-to-peak
amplitude during 3 of 5 consecutive trials on the orbicularis oris
◦ the sham stimulation occurred using the same protocol as that for the LF
stimulation, except that the angle of the coil was perpendicular to the skull rather that
tangential to it. Thus, the magnetic field could not penetrate the brain, although the
participants could hear the sound that was produced
◦ this group also received speech therapy for 30 minutes, 5 days per week from
a skilled speech therapist who was blind to the nature of the study during the 2-week
intervention period
• Start of intervention: between 1 week and 2 months
• Duration: 2 weeks
• Frequency: 30 minutes, 5 days/week
• Administration: physiatrist
• Fidelity: not described
• Location: Department of Rehabilitation Medicine
• Adherence: 3 participants were unable to complete the study in the intervention
group (10 completed)
• Adherence: 2 participants were unable to complete the study in the sham
stimulation group (10 completed)
• Homework: none
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Outcomes Outcomes used in this review. No primary outcome identified
• Urimal Test of Articulation and phonology (U-TAP)
• Alternative motion rates (AMR)
• Sequential motion rates (SMR)
• Maximal phonation time (MPT)
Dysarthria was evaluated by a single skilled speech therapist who was blind to the study
protocol before and after the rTMS sessions
These 4 measures were carried out prior to and immediately at the end of the 2-week
treatment period
Notes Funding source: not known
We were unsuccessful in contacting the first author of the study for further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation using a random numbers
table; odd numbers went to the repetitive
transcranial magnetic stimulation group
and even numbers went to the sham stimu-
lation group although it does not specify if
this was equal randomisation. Insufficient
information available
Allocation concealment (selection bias) Unclear risk Nodescription of whatmethodwas used to
ensure allocation concealment so this indi-
cates a potential risk in the absence of fur-
ther information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study reports the outcome assessor was
blinded to protocol but insufficient detail
as to how thiswas ensured; itmay have been
easy to break this blinding process
Incomplete outcome data (attrition bias)
All outcomes
High risk 5 participants were randomised to treat-
ment groups but then failed to complete
the treatment. These participants and their
data were withdrawn from all the analysis
and no consideration evident as to how this
missing data was dealt with
Selective reporting (reporting bias) Unclear risk In the absence of a protocol this remains
unclear
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Mackenzie 2014
Methods Study design: a feasibility RCT
Study duration: enrolment within 1 year
Participants Inclusion criteria
• Setting: community
• Country: Scotland
• Health status: stroke: minimum of 3 months since the last stroke, and dysarthria
diagnosed by a referring speech and language therapist
• Number: 39 recruited and randomised; Group A had 20 participants and group B
had 19 participants
• Age (mean, SD): intervention A: 62.80 ± 12.52; intervention B : 67.95 ± 12.10
• Sex (M/F): intervention A: 12/7; intervention B: 14/6
• Time post stroke/brain injury:
• ◦ intervention A in months: 10.84 ± 7.09
◦ intervention B in months 9.3 ± 5.12
• Severity of dysarthria: intervention A: mild 12/severe 7; intervention B: mild 9/
severe 11
• Other communication impairment: intervention A: 6/19 had aphasia;
intervention B: 6/20 had aphasia
Exclusion criteria
• co-existing neurological condition; Mini Mental State Examination score < 24;
Boston Diagnostic Aphasia Examination aphasia severity rating of 4 to 5; English not
first language; vision and hearing not adequate despite required augmentation
Interventions Intervention A group
• Intervention:
◦ group A had the following intervention of behavioural, activity level practice
of individually relevant speech sounds in words, sentences and conversation. Strategies
for optimising speech, slowed rate, emphasis of key syllables, deliberate articulation
were also used as required
◦ group A carried out 20 minutes of word and sentence practice as part of the
40-minute session
• Start of treatment: more than 3 months post stroke
• Duration: 8 weeks
• Frequency: 40 minutes once/week
• Administration: single experienced speech and language therapist
• Fidelity: monitored by research team and Health Boards at 2 sessions.
• Location: participants’ homes
• Adherence: intervention A:17/19 completed
• Homework: 10 to 15 minutes, 5 days/week (1050 minutes), recorded in diary,
85% practised 1050 minutes
Intervention B group
• Intervention:
◦ group B had the following intervention of behavioural, activity level practice
of individually relevant speech sounds in words, sentences and conversation. Strategies
for optimising speech, slowed rate, emphasis of key syllables, deliberate articulation
were also used as required
◦ group B also had non-speech oro-motor exercises (impairment level) and
carried out 10 minutes of word and sentence practice and 10 minutes of oro-motor
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exercises as part of the 40-minute session
• Duration: 8 weeks
• Frequency: 40 minutes once/week
• Administration: single experienced speech and language therapist
• Fidelity: monitored by research team and Health Boards at 2 sessions.
• Location: participants’ homes
• Adherence: intervention B:19/20 completed
• Homework: 10 to 15 minutes, 5 days/week (1050 minutes), recorded in diary,
85% practised 1050 minutes
Outcomes Outcomes used in this review. No primary outcome measure identified
• speech intelligibility at sentence level with Speech Intelligibility Test (SIT)
• communication effectiveness in conversation with Communication Effectiveness
Measure (CEM)
• lip and tongue movement tasks from Frenchay Dysarthria Assessment-2 (FDA-2)
• communicative Effectiveness Survey - self-rating of communication effectiveness
Intervention A lost 4/19 to follow-up
Intervention B lost 4/20 to follow-up
Notes Funding source: Dunhill Medical Trust
We requested further information, which was provided, as well as a telephone consulta-
tion
We were able to classify incomplete outcome data as low risk following discussion with
the study author. They clarified that they had statistically analysed their findings appro-
priately and this had not affected the results:
“Group A versus Group B difference was not indicated on any of the four measures,
based on data for 32 completing participants: SIT F(1, 30)=1.46, p=0.24; CEM F(1,
30) = 2.39, p = 0.13, CES F(1, 30) = 0.58, p = 0.45; FDA-2 F(1, 30) = 2.61, p = 0.12.
There was no significant interaction between group allocation and assessment point on
any of the four measures for these participants: SIT F(3, 90) = 0.88, p = 0.97; CEM F
(3, 90) = 0.34, p = 0.80; CES F(3, 90) = 0.16, p = 0.92; FDA F(3, 90) = 0.12, p = 0.
95. In view of the scale nature of the CEM measure, non-parametric analysis was also
undertaken and provided similar results. Imputation of results for seven additional cases
with incomplete intervention and/or post-intervention assessments, by last observation
carried forward and multiple imputation provided similar results for all measures.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer generated
and the block system was employed to fa-
cilitate the logistics of recruitment and in-
tervention. This would not affect sequence
generation. Patrticipants were referred in
batches of 8 and then randomised within
each block so 4 to group A and 4 to group
B
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Allocation concealment (selection bias) Low risk This was provided in opaque envelopes af-
ter the initial assessment by the ’assessor’
and just before the intervention treatment
started by the ’intervention’ researcher
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Single blinded experienced speech and lan-
guage therapy research assessor collected
the outcome measurements. These were
rated or transcribed by groups of blinded
graduating speech and language therapy
students
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome not likely to clinically im-
pact, discussed with study author and con-
firmed all data included and adjustedwhere
appropriate
Selective reporting (reporting bias) Low risk Feasibility study but all data and outcomes
reported
Wenke 2010
Methods Study design: RCT; an experimental research design was used to investigate the effects
of 2 treatments at multiple follow-up time points
Study duration: not known
Participants Inclusion criteria
• Setting: not known
• Country: Australia
• Health status: 6 months post onset of stroke or brain injury
• Number: 26 13 in the TRAD (traditional dysarthria therapy) intervention group
and 13 in the LSVT (Lee Silverman Voice Treatment) intervention group
• Age (mean, SD): total for study: 48.6 ± 21.3
• Sex (M/F): intervention A (TRAD): 7/6; intervention B (LSVT): 9/4(usual care)
• Time post stroke/brain injury:
◦ total study in years: 3.4 ± 4.75 (range: 5 to 21 years)
• Severity of dysarthria: intervention A: mild/moderate 7, moderate/severe 6;
intervention B: mild/moderate 7, moderate/severe 6
• Other communication impairment: intervention A cognitive impairment: 11/13;
intervention B: cognitive impairment: 10/13
Exclusion criteria
• Co-existing significant aphasia, hearing loss, dementia, apraxia of speech, post
traumatic amnesia, or pre-existing laryngeal pathology and/or dysfunction as identified
during a video laryngoscopic examination, people with a significant respiratory
dysfunction unrelated to the neurological disorder; unable to speak or understand
English, unable to increase/alter habitual vocal volume or quality during the pre-
treatment assessment
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Interventions Treatment group A
• Intervention:
◦ TRAD used behavioural techniques at impairment and activity level. This
involved phonation and/or oro-motor exercises, strategies to improve articulation,
respiratory/phonatory therapy, resonance and prosody exercises. Daily 5 to 10 minutes
of homework exercises. Maintenance task of exercises 5 to 10 minutes per day, 3 to 5
days a week, for 6 months were given at the end of treatment
• Duration: 4 weeks
• Frequency: intervention A: 1 hour/day, 4 days/week for 4 weeks
• Administration: speech pathologist certified in intervention; intervention A:
delivered by 1 speech pathologist
• Fidelity: not described
• Location: not known
• Adherence: intervention A: all completed
• Homework: intervention B: asked to practice 5 to 10 minutes daily homework
during treatment. Intervention A: on completion of 4 week treatment asked to practice
daily, 5 to 10 minutes, 3 to 5 days/week for 6 months. No description of whether
practice was recorded and this was not reported
Treatment group B
• Intervention:
◦ LSVT treatment was delivered in strict accordance with the manual by a
therapist trained in LSVT, which employs increased vocal loudness and maximum
physiological effort. Maintenance exercises were given following treatment to be carried
out for 5 to 10 minutes per day, 3 to 5 days a week, for 6 months
• Duration: 4 weeks
• Frequency: intervention B: 1 hour/day, 4 days/week for 4 weeks
• Administration: speech pathologist certified in intervention; intervention B:
delivered by 1 speech pathologist
• Fidelity: not described
• Location: not known
• Adherence: intervention B: all completed
• Homework: intervention B: asked to practice 5 to 10 minutes daily homework
during treatment. Intervention B: on completion of 4 week treatment asked to practice
daily, 5 to 10 minutes, 3 to 5 days/week for 6 months. No description of whether
practice was recorded and this was not reported
Outcomes 26 randomised
Intervention A lost 4/13 to some follow-up assessments
Intervention B lost 4/13 to some follow-up assessments
No primary outcome measure specified.
• Perceptual measure of articulatory precision and intelligibility using direct
magnitude estimation
• Acoustic analysis of vowels
• Acoustic analysis of consonants
We used intelligibility measure as the primary outcome measure at activity level and
articulatory precision as the secondary impairment level measure
The data presented in the paper analysed the vowels and consonants separately, which
meant data extraction was not possible without further information from the authors
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Notes Funding source: not known
Contact with study authors: the study authors responded to 1 email answering questions
relating to randomisation. We were unable to pursue a telephone consultation with the
authors to discuss further
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation according to
severity levelswas carried out and allocation
based on the results of this clinical judge-
ment. Computer generated randomisation
confirmed by author
Allocation concealment (selection bias) Unclear risk Further information suggested a pre-gen-
erated list was used and stored on a com-
puter in an Excel file, but it was not clear
who had access to this list and how easily
accessible this list was
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk 2 certified speech-language pathologists
served as independent listeners. This im-
plies they are not involved in the study but
does not specify whether they were blind
or not to the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk Unable to find outmore from study author;
missing outcome data showing imbalance
across the 2 groups
Selective reporting (reporting bias) Low risk All outcome measures reported at all time
points
Xu 2010
Methods Study design: RCT to observe the effect of acupuncture combined with speech therapy
for dysarthria versus speech therapy only
Study duration: not known
Participants Inclusion criteria
• Setting: hospital
• Country: China
• Health status: people diagnosed with stroke by CT and/or MRI; people diagnosed
as dysarthric by the hearing and speech specialist
• Number: 61; 30 in the intervention group (speech therapy and acupuncture); 31
in the control group (speech therapy only)
• Age (mean, SD): intervention A: 52.6 ± 12.7; control group: 52.2 ± 12.3
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Xu 2010 (Continued)
• Sex (M/F): intervention A: 23/7; control group: 26/5
• Time post stroke/brain injury:
◦ Intervention A in months: 2.80 ± 2.13
◦ Control group in months: 2.48 ± 1.69
• Severity of dysarthria: severe dysarthria excluded
• Other communication impairment: excluded from study
Exclusion criteria
• Mother tongue not Mandarin; severe dysarthria or dysarthria with aphasia and
apraxia of speech; cognitive impairment; could not tolerate speech therapy; Parkinsons
Disease or other cerebellar lesion; myocardial infarction or renal dysfunction, severe
infection or severe diabetes; unable to tolerate acupuncture, or having syncope
Interventions Treatment group (acupuncture)
• Intervention:
◦ Speech therapy intervention for both groups is impairment and activity level
intervention. Breathing training, articulation work, nasality work, tone and intonation
◦ Acupuncture at Lianquan (CV 23), Jinjin (EX-HN 12), Yuye (EX-HN 13),
Fengchi (GB 20), Yifeng (TE 17) and Wangu (GB 12) as major acupoints
◦ Acupuncture needles were inserted at the acupoints in different ways. The
needles were pulled out when the skin sites of the major acupoints Jinjin and Yuye
began to bleed. The needles inserted into the other major acupoints and additional
points except these two points were left for 30 minutes at a time
• Start of treatment: between 1 to 12 months post stroke/brain injury
• Duration: 9 weeks with 1 week of no treatment at week 5 and speech therapy
• Frequency: acupuncture for 30 minutes, 5 times/week and speech therapy for 30
minute sessions, 5 times per week for 9 weeks
• Administration: traditional Chinese medicine specialist delivered acupuncture
and speech therapy delivered by a speech therapist
• Fidelity: not described
• Location: hospital
• Adherence: intervention A: all completed
• Homework: none
Control group (usual care)
• Intervention:
◦ Speech therapy intervention for both groups is impairment and activity level
intervention. Breathing training, articulation work, nasality work, tone and intonation
• Duration: 9 weeks
• Frequency: 30 minutes, 5 times/week
• Administration: speech therapist
• Fidelity: not described
• Location: hospital
• Adherence: all completed
• Homework: none
Outcomes No primary outcome measure identified
Outcome measures used were:
• perceptual evaluation of articulation intelligibility using the Chinese
Rehabilitation Research Centre Dysarthria Examination method
• the maximum phonation time measuring air flow
Outcome measures carried out immediately post treatment when the 9-week treatment
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Xu 2010 (Continued)
period ended. The outcome measures were carried out before and immediately after the
trial by the hearing and speech specialists who did not know the details of the trial
No participants were lost to follow up from either group
Notes Funding source: not known
We were unsuccessful in contacting the first author of the study for further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Refers to a random number table but lim-
ited information make this judgment diffi-
cult
Allocation concealment (selection bias) Unclear risk There is no information about allocation
concealment without further discussion
with the author of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The participants were tested before and af-
ter the treatment by the same hearing and
speech therapist who did not know the
detail of the trial. This implies they were
blinded to the intervention but no further
information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appears to have no missing data with all
participants recruited remaining in the trial
to follow-up
Selective reporting (reporting bias) Unclear risk Wewere unable to verify selective reporting
after an unsuccessful attempt to contact the
authors
CT: computer tomography
ITT: intention-to-treat
MRI: magnetic resonance imaging
RCT: randomised controlled trial
SLT: speech and language therapist
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Behn 2011 Excluded people with dysarthria
Behn 2012 Intervention for carers not people with dysarthria
Braverman 1999 RCT; included people with communication problems other than dysarthria
Intervention for cognition not dysarthria
Cohen 1993 Mixed aetiology of progressive and non-progressive adult-acquired and congenital brain injury
Fitzgerald-DeJean 2008 Not an RCT; wrong intervention (language)
Fukusako 1989 Not an RCT
Garcia 1998 Not an RCT
Huffman 1978 Not an RCT
Huh 2014 Not an RCT
Hustad 2003 Not an RCT
Ince 1973 Not an RCT
Jones 1972 Not an RCT
Kati 1973 Not an RCT
Kelly 2000 Mixed aetiology of participants, progressive and non-progressive
Li 2013 Not an RCT
Main 1998 Mixed aetiology of participants, progressive and non-progressive
Markov 1973 Not an RCT
Nagasawa 1970 Not an RCT
Palmer 2004 Not an RCT
Palmer 2007 Not an RCT
Qinglan 2002 Wrong intervention (surgical)
Robertson 2001 Not an RCT
Rosenbek 2006 Not an RCT
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(Continued)
Sakharov 2013 Not an RCT
Sze 2002 Intervention not for people with dysarthria
Togher 2004 Intervention not for people with dysarthria
Togher 2014 Not an RCT
Varma 2004 Not an RCT
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
You 2010
Methods The effects of transcranial direct stimulation (tDCS) on dysarthria in stroke patients
In a prospective, double blinded, randomised case control study performed between January 2007 and December
2008, 6 people were randomised to anodal tDCS application and conventional speech therapy, and 6 participants
were randomised to the sham group, which received only conventional speech therapy. tDCS was delivered for 30
minutes at 2 milliampere (mA) with 25 cm², five times/week, for a total of 2 weeks. The effects were assessed in
maximal phonation time (MPT), alternative motion rates (AMR)-Pa, AMR-Ta, AMR-Ka, and sequential motion
rates (SMR)-PaTaKa using the Multi-Media Dimension Voice Program
Participants 12 participants who developed dysarthria after acute middle cerebral artery infarction were included in this study
Interventions Experimental intervention: anodal tDCS application and conventional speech therapy
Usual care intervention: conventional speech therapy only
Outcomes Pre-treatment patient evaluation showed no significant difference between the 2 groups for all parameters. The MPT,
AMR-Pa, AMR-Ta, AMR-Ka, and SMR-PaTaKa were improved pre- and post-treatment in the stimulation group,
while MPT, SMR-PaTaKa were improved in the sham group (P < 0.05). The AMR-Pa significantly improved in the
stimulation group compared with the sham group (P < 0.05)
Notes This study is in Korean and needs to be translated and data extracted before it can be considered for inclusion in the
review. We were unsuccessful in contacting the first author for further information
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Characteristics of ongoing studies [ordered by study ID]
Peng 2015
Trial name or title Modified VitalStim electroacupuncture improves the speech function in people with spastic dysarthria after
stroke
Methods 32 people with spastic dysarthria after stroke within 1 month were randomly divided into VitalStim group (n
= 16) and control group (n = 16). Basic medical therapy, physical therapy, occupational therapy, and speech
therapywere used in both groups. Additionally,modifiedVitalStim electroacupuncture at acupoints of Yiming
(EXHN14), Fengchi (GB20), Dazhui (BU14), Lianquan (RN23), Baihui (DU20), and lateral Jinjinyuye was
performed in Vitalstim group. Participants in VitalStim group received extra 30-minute VitalStim therapy
once a day, for a total of 28 days. The outcomes were evaluated by using modified Barthel index (MBI) and
Frenchay Dysarthria Assessment (FDA), and the practical significance of VitalStim electroacupuncture were
statistical analysed
Participants 32 participants with spastic dysarthria after stroke within 1 month
Interventions Basic medical therapy, physical therapy, occupational therapy, and speech therapy were used in both groups.
Additionally, modified VitalStim electroacupuncture at acupoints of Yiming (EXHN14), Fengchi (GB20),
Dazhui (BU14), Lianquan (RN23), Baihui (DU20) and lateral Jinjinyuye was performed in Vitalstim group.
Participants in the VitalStim group received extra 30-minute VitalStim therapy once a day, for a total of 28
days
Outcomes The outcomes were evaluated by using modified Barthel index (MBI) and Frenchay Dysarthria Assessment
(FDA). MBI increased significantly after treatment in both groups (P < 0.01). Compared with both groups,
MBI increased more significantly in VitalStim group (P < 0.05). Significant improvements were found in
VitalStim group in relation to 20 FDA items, such as lips spread, tongue at rest and palate maintenance
(P < 0.05). The performance of the patients in VitalStim group on the rest of FDA items also showed an
improvement trend compared with that of control (P > 0.05) except for the two items in relation to tongue
alternate and jaw in speech
Starting date Not known
Contact information YN Peng, Y Yin, BT Tan, W Jiang, B Zheng, YY Deng, LH Yu
The Second Affiliated Hospital of Chongqing Medical University, Rehabilitation Medicine, Chongqing,
China
Chongqing Medical University, Rehabilitation Therapy, Chongqing, China
Notes This study is available as an abstract only and no full report can be found. We unsuccessfully attempted
to contact the authors to obtain further information about this study, including if the full study has been
published
WCPT Congress 2015/Physiotherapy 2015; 101 (Suppl 1): eS833-eS1237 eS1189
Ethics approval: Ethical approval obtained from the Ethics Committee of the Second Affiliated Hospital
of Chongqing Medical University. http://dx.doi.org/10.1016/j.physio.2015.03.2113 Research Report Poster
Presentation
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ReaDySpeech
Trial name or title ReaDySpeech for people with dysarthria after stroke: protocol for a feasibility RCT
Methods A feasibility RCT will recruit 36 people with post-stroke dysarthria who are more than 1 week post-stroke.
Participants will be externally randomised in a 2:1 ratio to receive either ReaDySpeech and usual care (24
participants) or usual care only (12 participants). This study is single blind with the researcher carrying out
the baseline and outcome measures blinded to treatment allocation. The primary objective is to assess the
feasibility of conducting a definitive trial. Secondary objectives include recruitment rate, and determining:
numbers of eligible patients recruited and reasons for non-recruitment; loss of participants to follow-up and
reasons; acceptability of randomisation and the intervention; adherence to the intervention; acceptability of
outcome measures; defining ’usual’ care; and the implications of the intervention for the patient/family/carer
Participants The study population includes adults (aged ≥18 years) with dysarthria as a result of stroke
Interventions ReaDySpeech is an online programme which delivers articulation exercises to improve breathing; intonation;
facial expression; rate of speech; and oro-motor control (including range of movement, strength and speed)
. ReaDySpeech is set up and amended by the treating therapist according to the participant’s progress. The
participant accesses these exercises online, via anyWi-Fi enabled device (smart phone, tablet computer, laptop
computer or personal computer). It can be used in a variety of ways: as part of face-to-face therapy during a
session with a speech and language therapist or a therapy assistant, or the participant can use it independently
outside of the therapy sessions, with or without the support of family or carers. The therapists select clinically
relevant exercises and negotiate agreed intensity and duration of use with the participant, adherence to which
is monitored by the software programme which will record the exercises selected by the therapist. Therapists
will have an instruction booklet with screen shots to support their use of ReaDySpeech. The proof of concept
work has shown that ReaDySpeech can be delivered by any qualified speech and language therapist of any
level of experience. In this trial, participating therapists will use ReaDySpeech with participants who meet
the inclusion criteria alongside ’usual’ care for a maximum of 10 weeks. No specifications about the intensity
of ReaDySpeech care will be made and this will be decided according to the therapist’s clinical judgement in
consultation with the participant
Outcomes Primary outcome: Dysarthria Therapy Outcome Measure (Therapist-reported activity level measure)
Secondary outcomes: COAST (communication outcome after stroke scale), Dysarthria Impact Profile (pa-
tient-reported outcome measure, activity and participation level), Frenchay Dysarthria Assessment 2nd edi-
tion (therapist-reported impairment level measure); Euroquol 5D-5L (patient-reported generic health out-
come measure)
Starting date September 2015
Contact information claire.mitchell@manchester.ac.uk
Notes ISRCTN84996500
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D A T A A N D A N A L Y S E S
Comparison 1. Dysarthria intervention compared with another intervention, attention control, placebo or no
intervention: persisting effects
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcome of dysarthria
intervention versus any control:
persisting effects, activity level
3 116 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.18, 0.55]
2 Secondary outcome of dysarthria
intervention versus any control:
persisting effects, impairment
level
2 56 Std. Mean Difference (IV, Random, 95% CI) 0.07 [-0.91, 1.06]
3 Secondary outcome of dysarthria
intervention versus any control:
persisting effects, participation
level
2 79 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.56, 0.33]
4 Primary outcome of dysarthria
intervention versus any control:
persisting effects, activity
level: adequate allocation
concealment/adequate blinding
2 92 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.30, 0.73]
5 Secondary outcome of dysarthria
intervention versus attention
control, placebo or no
intervention: persisting effects,
activity level
1 60 Std. Mean Difference (IV, Random, 95% CI) 0.0 [-0.51, 0.51]
6 Secondary outcome of dysarthria
intervention versus any control
for stroke subgroup: persisting
effects, activity level
3 106 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.23, 0.54]
Comparison 2. Dysarthria Intervention compared with another intervention, attention control, placebo or no
intervention: immediate effects
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Seconday outcome of dysarthria
intervention versus any control:
immediate effects, activity level
3 117 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.07, 0.66]
2 Secondary outcome of dysarthria
intervention versus any control:
immediate effects, impairment
level
4 99 Std. Mean Difference (IV, Random, 95% CI) 0.47 [0.02, 0.92]
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3 Secondary outcome of dysarthria
intervention versus any control:
immediate effects, participation
level
1 32 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.94, 0.45]
Comparison 3. Dysarthria intervention A versus dysarthria intervention B: persisting and immediate effects
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Secondary outcome of dysarthria
intervention A versus dysarthria
intervention B: persisting
effects, activity level
2 56 Std. Mean Difference (IV, Random, 95% CI) 0.38 [-0.15, 0.91]
2 Secondary outcome of dysarthria
intervention A versus dysarthria
intervention B: persisting
effects, participation level
1 32 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.92, 0.47]
Analysis 1.1. Comparison 1 Dysarthria intervention compared with another intervention, attention
control, placebo or no intervention: persisting effects, Outcome 1 Primary outcome of dysarthria intervention
versus any control: persisting effects, activity level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 1 Dysarthria intervention compared with another intervention, attention control, placebo or no intervention: persisting effects
Outcome: 1 Primary outcome of dysarthria intervention versus any control: persisting effects, activity level
Study or subgroup Any control Any control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bowen 2012 33 3.1 (1.4) 27 3.1 (1.7) 52.2 % 0.0 [ -0.51, 0.51 ]
Mackenzie 2014 16 4.92 (1.44) 16 4.09 (1.56) 27.0 % 0.54 [ -0.17, 1.25 ]
Wenke 2010 13 121.4 (36.4) 11 110.25 (79.9) 20.8 % 0.18 [ -0.63, 0.98 ]
Total (95% CI) 62 54 100.0 % 0.18 [ -0.18, 0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.47, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Any control Dysarthria intervention
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Analysis 1.2. Comparison 1 Dysarthria intervention compared with another intervention, attention
control, placebo or no intervention: persisting effects, Outcome 2 Secondary outcome of dysarthria
intervention versus any control: persisting effects, impairment level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 1 Dysarthria intervention compared with another intervention, attention control, placebo or no intervention: persisting effects
Outcome: 2 Secondary outcome of dysarthria intervention versus any control: persisting effects, impairment level
Study or subgroup
Dysarthria
interven-
tion Any control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mackenzie 2014 16 42.46 (6.21) 16 38.73 (6.87) 52.1 % 0.56 [ -0.15, 1.26 ]
Wenke 2010 13 114.16 (33.8) 11 127.64 (21.87) 47.9 % -0.45 [ -1.26, 0.37 ]
Total (95% CI) 29 27 100.0 % 0.07 [ -0.91, 1.06 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 3.32, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Any control Dysarthria intervention
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Analysis 1.3. Comparison 1 Dysarthria intervention compared with another intervention, attention
control, placebo or no intervention: persisting effects, Outcome 3 Secondary outcome of dysarthria
intervention versus any control: persisting effects, participation level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 1 Dysarthria intervention compared with another intervention, attention control, placebo or no intervention: persisting effects
Outcome: 3 Secondary outcome of dysarthria intervention versus any control: persisting effects, participation level
Study or subgroup
Dysarthria
interven-
tion Any control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bowen 2012 28 74.523 (19.233) 19 75.18 (12.96169) 58.8 % -0.04 [ -0.62, 0.54 ]
Mackenzie 2014 16 19.94 (5.97) 16 21.25 (5.48) 41.2 % -0.22 [ -0.92, 0.47 ]
Total (95% CI) 44 35 100.0 % -0.11 [ -0.56, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Any control Dysarthria intervention
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Analysis 1.4. Comparison 1 Dysarthria intervention compared with another intervention, attention
control, placebo or no intervention: persisting effects, Outcome 4 Primary outcome of dysarthria intervention
versus any control: persisting effects, activity level: adequate allocation concealment/adequate blinding.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 1 Dysarthria intervention compared with another intervention, attention control, placebo or no intervention: persisting effects
Outcome: 4 Primary outcome of dysarthria intervention versus any control: persisting effects, activity level: adequate allocation concealment/adequate blinding
Study or subgroup
Dysarthria
interven-
tion Any control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bowen 2012 33 3.1 (1.4) 27 3.1 (1.7) 60.8 % 0.0 [ -0.51, 0.51 ]
Mackenzie 2014 16 4.92 (1.44) 16 4.09 (1.56) 39.2 % 0.54 [ -0.17, 1.25 ]
Total (95% CI) 49 43 100.0 % 0.21 [ -0.30, 0.73 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 1.47, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Any control Dysarthria intervention
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Analysis 1.5. Comparison 1 Dysarthria intervention compared with another intervention, attention
control, placebo or no intervention: persisting effects, Outcome 5 Secondary outcome of dysarthria
intervention versus attention control, placebo or no intervention: persisting effects, activity level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 1 Dysarthria intervention compared with another intervention, attention control, placebo or no intervention: persisting effects
Outcome: 5 Secondary outcome of dysarthria intervention versus attention control, placebo or no intervention: persisting effects, activity level
Study or subgroup
Dysarthria
interven-
tion Any control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bowen 2012 33 3.1 (1.4) 27 3.1 (1.7) 100.0 % 0.0 [ -0.51, 0.51 ]
Total (95% CI) 33 27 100.0 % 0.0 [ -0.51, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Any control Dysarthria intervention
Analysis 1.6. Comparison 1 Dysarthria intervention compared with another intervention, attention
control, placebo or no intervention: persisting effects, Outcome 6 Secondary outcome of dysarthria
intervention versus any control for stroke subgroup: persisting effects, activity level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 1 Dysarthria intervention compared with another intervention, attention control, placebo or no intervention: persisting effects
Outcome: 6 Secondary outcome of dysarthria intervention versus any control for stroke subgroup: persisting effects, activity level
Study or subgroup
Dysarthria
interven-
tion Any control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bowen 2012 33 3.1 (1.4) 27 3.1 (1.7) 57.2 % 0.0 [ -0.51, 0.51 ]
Mackenzie 2014 16 4.92 (1.44) 16 4.09 (1.56) 29.6 % 0.54 [ -0.17, 1.25 ]
Wenke 2010 129.6667 (59.815) 6 8 131.63 (58.70979) 13.2 % -0.03 [ -1.09, 1.03 ]
Total (95% CI) 55 51 100.0 % 0.16 [ -0.23, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.61, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Any control Dysarthria intervention
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Analysis 2.1. Comparison 2 Dysarthria Intervention compared with another intervention, attention
control, placebo or no intervention: immediate effects, Outcome 1 Seconday outcome of dysarthria
intervention versus any control: immediate effects, activity level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 2 Dysarthria Intervention compared with another intervention, attention control, placebo or no intervention: immediate effects
Outcome: 1 Seconday outcome of dysarthria intervention versus any control: immediate effects, activity level
Study or subgroup
Dysarthria
interven-
tion Any control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mackenzie 2014 16 4.93 (1.48) 16 4.1 (1.57) 26.7 % 0.53 [ -0.18, 1.24 ]
Wenke 2010 13 102.14 (30.07) 11 96.23 (55.31) 20.7 % 0.13 [ -0.67, 0.94 ]
Xu 2010 30 55.83 (15.26) 31 52.25 (14.65) 52.6 % 0.24 [ -0.27, 0.74 ]
Total (95% CI) 59 58 100.0 % 0.29 [ -0.07, 0.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours [control] Favours [experimental]
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Analysis 2.2. Comparison 2 Dysarthria Intervention compared with another intervention, attention
control, placebo or no intervention: immediate effects, Outcome 2 Secondary outcome of dysarthria
intervention versus any control: immediate effects, impairment level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 2 Dysarthria Intervention compared with another intervention, attention control, placebo or no intervention: immediate effects
Outcome: 2 Secondary outcome of dysarthria intervention versus any control: immediate effects, impairment level
Study or subgroup
Dysarthria
interven-
tion Any control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kwon 2015 10 100 (0) 10 98.1 (4.7) Not estimable
Mackenzie 2014 16 41.36 (6.4) 16 37.06 (6.58) 39.8 % 0.65 [ -0.07, 1.36 ]
Wenke 2010 13 110.28 (27.54) 11 102.28 (52.39) 31.2 % 0.19 [ -0.62, 0.99 ]
Xu 2010 12 8.84 (3.03) 11 7.3 (2.37) 29.0 % 0.54 [ -0.29, 1.38 ]
Total (95% CI) 51 48 100.0 % 0.47 [ 0.02, 0.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Any control Dysarthria intervention
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Analysis 2.3. Comparison 2 Dysarthria Intervention compared with another intervention, attention
control, placebo or no intervention: immediate effects, Outcome 3 Secondary outcome of dysarthria
intervention versus any control: immediate effects, participation level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 2 Dysarthria Intervention compared with another intervention, attention control, placebo or no intervention: immediate effects
Outcome: 3 Secondary outcome of dysarthria intervention versus any control: immediate effects, participation level
Study or subgroup
Dysarthria
interven-
tion Any control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mackenzie 2014 16 20.13 (6.53) 16 21.56 (4.8) 100.0 % -0.24 [ -0.94, 0.45 ]
Total (95% CI) 16 16 100.0 % -0.24 [ -0.94, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Any control Dysarthria intervention
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Analysis 3.1. Comparison 3 Dysarthria intervention A versus dysarthria intervention B: persisting and
immediate effects, Outcome 1 Secondary outcome of dysarthria intervention A versus dysarthria intervention
B: persisting effects, activity level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 3 Dysarthria intervention A versus dysarthria intervention B: persisting and immediate effects
Outcome: 1 Secondary outcome of dysarthria intervention A versus dysarthria intervention B: persisting effects, activity level
Study or subgroup Intervention A Intervention B
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mackenzie 2014 16 4.92 (1.44) 16 4.09 (1.56) 56.4 % 0.54 [ -0.17, 1.25 ]
Wenke 2010 13 121.4 (36.4) 11 110.25 (79.9) 43.6 % 0.18 [ -0.63, 0.98 ]
Total (95% CI) 29 27 100.0 % 0.38 [ -0.15, 0.91 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Intervention B Intervention A
Analysis 3.2. Comparison 3 Dysarthria intervention A versus dysarthria intervention B: persisting and
immediate effects, Outcome 2 Secondary outcome of dysarthria intervention A versus dysarthria intervention
B: persisting effects, participation level.
Review: Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury
Comparison: 3 Dysarthria intervention A versus dysarthria intervention B: persisting and immediate effects
Outcome: 2 Secondary outcome of dysarthria intervention A versus dysarthria intervention B: persisting effects, participation level
Study or subgroup Intervention A Intervention B
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mackenzie 2014 16 19.94 (5.97) 16 21.25 (5.48) 100.0 % -0.22 [ -0.92, 0.47 ]
Total (95% CI) 16 16 100.0 % -0.22 [ -0.92, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Intervention B Intervention A
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A P P E N D I C E S
Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
Cochrane Library databases (CDSR, DARE, CENTRAL, HTA) searched to May 2016
1. MeSH descriptor: [Cerebrovascular Disorders] this term only
2. MeSH descriptor: [Basal Ganglia Cerebrovascular Disease] explode all trees
3. MeSH descriptor: [Brain Ischemia] explode all trees
4. MeSH descriptor: [Carotid Artery Diseases] explode all trees
5. MeSH descriptor: [Cerebrovascular Trauma] explode all trees
6. MeSH descriptor: [Intracranial Arteriovenous Malformations] explode all trees
7. MeSH descriptor: [Intracranial Arterial Diseases] explode all trees
8. MeSH descriptor: [Intracranial Embolism and Thrombosis] explode all trees
9. MeSH descriptor: [Intracranial Hemorrhages] explode all trees
10. MeSH descriptor: [Stroke] this term only
11. MeSH descriptor: [Brain Infarction] explode all trees
12. MeSH descriptor: [Stroke, Lacunar] this term only
13. MeSH descriptor: [Vasospasm, Intracranial] this term only
14. MeSH descriptor: [Vertebral Artery Dissection] this term only
15. MeSH descriptor: [Hypoxia, Brain] explode all trees
16. stroke* or “post stroke” or poststroke or post-stroke or apoplex* or cerebrovasc* or CVA or SAHor “cerebral vasc*” (Word variations
have been searched)
17. (brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or
“middle cerebr*” or mca* or “anterior circulaion” or “basilar artery” or “vertebral artery”) and (ischaemi* or ischemi* or thrombos* or
thromboem* or emboli* or occlus* or hypoxi*) (Word variations have been searched)
18. (brain* or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or “basal gangli*” or putaminal or putamen or “posterior fossal” or hemisphere* or subarachnoid) and (haemorrhag*
or hemorrhag* or haematoma* or bleed*) (Word variations have been searched)
19. MeSH descriptor: [Hemiplegia] explode all trees
20. MeSH descriptor: [Paresis] explode all trees
21. MeSH descriptor: [Aphasia] explode all trees
22. MeSH descriptor: [Gait Disorders, Neurologic] explode all trees
23. (hemipar* or hemipleg* or paresis or paretic or aphasi* or dysphasi*) (Word variations have been searched)
24. MeSH descriptor: [Brain Damage, Chronic] explode all trees
25. MeSH descriptor: [Brain Injuries] this term only
26. MeSH descriptor: [Brain Concussion] explode all trees
27. MeSH descriptor: [Brain Hemorrhage, Traumatic] explode all trees
28. MeSH descriptor: [Brain Injury, Chronic] this term only
29. MeSH descriptor: [Diffuse Axonal Injury] this term only
30. MeSH descriptor: [Craniocerebral Trauma] this term only
31. MeSH descriptor: [Head Injuries, Closed] explode all trees
32. MeSH descriptor: [Intracranial Hemorrhage, Traumatic] explode all trees
33. MeSH descriptor: [Brain Abscess] explode all trees
34. MeSH descriptor: [Central Nervous System Infections] explode all trees
35. MeSH descriptor: [Encephalitis] explode all trees
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36. MeSH descriptor: [Meningitis] explode all trees
37. (encephalitis or meningitis or “head injur*”) (Word variations have been searched)
38. MeSH descriptor: [Brain Neoplasms] explode all trees
39. (brain or cerebr*) and (injur* or hypoxi* or damage* or concussion or trauma* or neoplasm* or lesion* or tumor* or tumour* or
cancer* or infection) (Word variations have been searched)
40.{or #1-#39}
41. MeSH descriptor: [Dysarthria] this term only
42. MeSH descriptor: [Articulation Disorders] this term only
43. MeSH descriptor: [Speech Articulation Tests] this term only
44. MeSH descriptor: [Speech Disorders] this term only
45. MeSH descriptor: [Voice Disorders] this term only
46. MeSH descriptor: [Aphonia] this term only
47. MeSH descriptor: [Dysphonia] this term only
48. MeSH descriptor: [Communication Disorders] this term only
49. (dysarth* or dysphon* or anarth* or dyspros* or aphon* or dysfluen* or stutter* or stammer*) (Word variations have been searched)
50. (speech or articul* or disarticul* or phonat* or phonolog* or voice or vocal or prosod* or intonat* or respirat* or communicat* or
fluen*) and (disorder* or impair* or problem* or difficult*) (Word variations have been searched)
51. speech and (slow* or weak* or imprecis* or intelligibil* or unintelligibil* or accuracy or fatigue) (Word variations have been searched)
52. {or #41-51}
53. MeSH descriptor: [Mouth] explode all trees
54. MeSH descriptor: [Larynx] explode all trees
55. MeSH descriptor: [Laryngeal Muscles] explode all trees
56. MeSH descriptor: [Pharynx] explode all trees
57. MeSH descriptor: [Pharyngeal Muscles] explode all trees
58. MeSH descriptor: [Facial Muscles] this term only
59. MeSH descriptor: [Palatal Muscles] this term only
60. (mouth or tongue or lingual or palat* or laryn* or pharyn* or orofacial or oro-facial or “face musc*” or facial musc*) (Word variations
have been searched)
61. {or #53-#60}
62. MeSH descriptor: [Movement Disorders] this term only
63. MeSH descriptor: [Ataxia] this term only
64. MeSH descriptor: [Dystonia] this term only
65. MeSH descriptor: [Dystonic Disorders] this term only
66. MeSH descriptor: [Hyperkinesis] this term only
67. MeSH descriptor: [Hypokinesia] explode all trees
68. MeSH descriptor: [Muscle Hypertonia] this term only
69. MeSH descriptor: [Muscle Hypotonia] this term only
70. MeSH descriptor: [Muscle Weakness] this term only
71. MeSH descriptor: [Muscular Diseases] this term only
72. MeSH descriptor: [Muscle Spasticity] this term only
73.( atax* or dyston* or hyperkin* or hypokin* or hypoton* or hyperton* or flaccid* or spastic*) (Word variations have been searched)
74. {or #62-#73}
75. #61 and #74
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Appendix 2. MEDLINE (PubMed) search strategy
MEDLINE (PubMed) from 1946 to May 2016
1. Search ((“Cerebrovascular Disorders”[Mesh:noexp]) OR “Basal Ganglia Cerebrovascular Disease”[Mesh]) OR “Brain Is-
chemia”[Mesh]) OR “Carotid Artery Diseases”[Mesh]) OR “Cerebrovascular Trauma”[Mesh]) OR “Intracranial Arteriovenous Mal-
formations”[Mesh]) OR “Intracranial Arterial Diseases”[Mesh]) OR “Intracranial Embolism and Thrombosis”[Mesh]) OR “Intracra-
nial Hemorrhages”[Mesh]) OR “Stroke”[Mesh:noexp]) OR “Brain Infarction”[Mesh]) OR “Stroke, Lacunar”[Mesh:noexp]) OR “Va-
sospasm, Intracranial”[Mesh:noexp]) OR “Vertebral Artery Dissection”[Mesh:noexp]) OR “Hypoxia, Brain”[Mesh])
2. Search (stroke*[TextWord] OR “post stroke”[TextWord] OR poststroke[Text Word] OR post-stroke[Text Word] OR apoplex*[Text
Word] OR cerebrovasc*[Text Word] OR CVA[Text Word] OR SAH[Text Word] OR cerebral vasc*[Text Word])
3. Search ((brain[Text Word] OR cerebr*[Text Word] OR cerebell*[Text Word] OR vertebrobasil*[Text Word] OR hemispher*[Text
Word] OR intracran*[Text Word] OR intracerebral[Text Word] OR infratentorial[Text Word] OR supratentorial[Text Word] OR
middle cerebr*[Text Word] OR mca*[Text Word] OR anterior circulation[Text Word] OR basilar artery[Text Word] OR vertebral
artery[Text Word])) AND (Ischemi*[Text Word] OR infarct*[Text Word] OR thrombos*[Text Word] OR thromboem*[Text Word]
OR emboli*[Text Word] OR occlus*[Text Word] OR hypoxi*[Text Word]))
4. Search (((Brain*[Text Word] OR cerebr*[Text Word] OR cerebell*[Text Word] OR intracerebral[Text Word] OR intracran*[Text
Word] ORparenchymal[TextWord] OR intraparenchymal[TextWord] OR intraventricular[TextWord] OR infratentorial[TextWord]
OR supratentorial[Text Word] OR basal gangli*[Text Word] OR putaminal[Text Word] OR putamen[Text Word] OR posterior
fossa[Text Word] OR hemisphere*[TextWord] OR subarachnoid[Text Word])) AND (haemorrhag*[TextWord] OR hemorrhag*[Text
Word] OR haematoma*[Text Word] OR hematoma*[Text Word] OR bleed*[Text Word]))
5. Search ((“Hemiplegia”[Mesh]) OR “Paresis”[Mesh]) OR “Aphasia”[Mesh]) OR “Gait Disorders, Neurologic”[Mesh])
6. Search (Hemipar*[Text Word] OR hemipleg*[Text Word] OR paresis[Text Word] OR paretic[Text Word] OR aphasi*[Text Word]
OR dysphasi*[Text Word])
7. Search ((“Brain Damage, Chronic”[Mesh]) OR “Brain Injuries”[Mesh:noexp]) OR “Brain Concussion”[Mesh]) OR “Brain Hem-
orrhage, Traumatic”[Mesh]) OR “Brain Injury, Chronic”[Mesh:noexp]) OR “Diffuse Axonal Injury”[Mesh:noexp])
8. Search ((“Craniocerebral Trauma”[Mesh:noexp]) OR “Head Injuries, Closed”[Mesh]) OR “Intracranial Hemorrhage, Trau-
matic”[Mesh])
9. Search ((“Brain Abscess”[Mesh]) OR “Central Nervous System Infections”[Mesh]) OR “Encephalitis”[Mesh]) OR “Meningi-
tis”[Mesh])
10. Search (encephalitis[Text Word] OR meningitis[Text Word] OR head injur*[Text Word])
11. Search “Brain Neoplasms”[Mesh]
12. Search (((brain[Text Word] OR cerebr*[Text Word])) AND (injur*[Text Word] OR hypoxi*[Text Word] OR damage*[Text Word]
OR concussion[Text Word] OR trauma*[Text Word] OR neoplasm*[Text Word] OR lesion*[Text Word] OR tumor*[Text Word] OR
tumour*[Text Word] OR cancer*[Text Word] OR infection[Text Word]))
13. Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
14. Search ((“Dysarthria”[Mesh:noexp]) OR “Articulation Disorders”[Mesh:noexp]) OR “Speech Articulation Tests”[Mesh:noexp])
15. Search (“Speech Disorders”[Mesh:noexp]) OR “Voice Disorders”[Mesh:noexp]) OR “Aphonia”[Mesh:noexp]) OR “Dyspho-
nia”[Mesh:noexp]) OR “Communication Disorders”[Mesh:noexp])
16. Search (dysarth*[TextWord] OR dysphon*[TextWord] OR anarth*[TextWord] OR dyspros*[TextWord] OR aphon*[TextWord]
OR dysfluen*[Text Word] OR stutter*[Text Word] OR stammer*[Text Word])
17. Search (((speech[Text Word] OR articul*[Text Word] OR disarticul*[Text Word] OR phonat*[Text Word] OR phonolog*[Text
Word] OR voice[Text Word] OR vocal[Text Word] OR prosod*[Text Word] OR intonat*[Text Word] OR respirat*[Text Word] OR
communicat*[Text Word] OR fluen*[Text Word])) AND (disorder*[Text Word] OR impair*[Text Word] OR problem*[Text Word]
OR difficult*[Text Word]))
18. Search (speech[Text Word]) AND (slow*[Text Word] OR weak*[Text Word] OR imprecis*[Text Word] OR intelligibil*[Text
Word] OR unintelligibil*[Text Word] OR accuracy[Text Word] OR fatigue[Text Word])
19. Search (“Mouth”[Mesh]) OR “Larynx”[Mesh]) OR “Laryngeal Muscles”[Mesh]) OR “Pharynx”[Mesh:noexp]) OR “Pharyngeal
Muscles”[Mesh]) OR “Facial Muscles”[Mesh:noexp]) OR “Palatal Muscles”[Mesh:noexp])
20. Search (mouth[Text Word] OR tongue[Text Word] OR lingual[Text Word] OR palat*[Text Word] OR laryn*[Text Word] OR
pharyn*[Text Word] OR orofacial[Text Word] OR oro-facial[Text Word] OR face musc*[Text Word] OR facial musc*[Text Word])
21. Search (#19 OR #20)
22. Search (“Movement Disorders”[Mesh:noexp]) OR “Ataxia”[Mesh:noexp]) OR “Dystonia”[Mesh:noexp]) OR “Dystonic Disor-
ders”[Mesh:noexp]) OR “Hyperkinesis”[Mesh:noexp]) OR “Hypokinesia”[Mesh:noexp]) OR “Muscle Hypertonia”[Mesh:noexp]) OR
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“Muscle Hypertonia”[Mesh]) OR “Muscle Hypotonia”[Mesh:noexp]) OR “Muscle Weakness”[Mesh:noexp]) OR “Muscular Dis-
eases”[Mesh:noexp]) OR “Muscle Spasticity”[Mesh:noexp])
23. Search (atax*[TextWord] OR dyston*[TextWord] OR hyperkin*[TextWord] OR hypokin*[TextWord] OR hypoton*[TextWord]
OR hyperton*[Text Word] OR flaccid*[Text Word] OR spastic*[Text Word])
24. Search (#22 OR #23)
25. Search (#21 AND #24)
26. Search (#14 OR #15 OR #16 OR #17 OR #18 OR #25)
27. Search “Randomized Controlled Trials as Topic”[Mesh:noexp]
28. Search “Random Allocation”[Mesh:noexp]
29. Search “Controlled Clinical Trials as Topic”[Mesh:noexp]
30. Search “Control Groups”[Mesh:noexp]
31. Search (“Clinical Trials as Topic”[Mesh:noexp]) OR “Clinical Trials, Phase I as Topic”[Mesh:noexp]) OR “Clinical Trials, Phase II
as Topic”[Mesh:noexp]) OR “Clinical Trials, Phase III as Topic”[Mesh:noexp]) OR “Clinical Trials, Phase IV as Topic”[Mesh:noexp])
32. Search “Double-Blind Method”[Mesh:noexp]
33. Search “Single-Blind Method”[Mesh:noexp]
34. Search “Placebos”[Mesh:noexp]
35. Search “Placebo Effect”[Mesh:noexp]
36. Search “Cross-Over Studies”[Mesh:noexp]
37. Search randomized controlled trial[Publication Type]
38. Search controlled clinical trial[Publication Type]
39. Search (clinical trial[Publication Type] OR clinical trial, phase i[Publication Type] OR clinical trial, phase ii[Publication Type] OR
clinical trial, phase iii[Publication Type] OR clinical trial, phase iv[Publication Type])
40. Search (random*[Text Word] OR RCT[Text Word] OR RCTs[Text Word])
41. Search (controlled[Text Word]) AND (trial*[Text Word] OR stud*[Text Word])
42. Search (clinical*[Text Word] AND trial*[Text Word])
43. Search (control[Text Word] OR treatment[Text Word] OR experiment*[Text Word] OR intervention[Text Word])) AND
(group*[Text Word] OR subject*[Text Word] OR patient*[Text Word])
44. Search (quasi-random*[Text Word] OR quasi random*[Text Word] OR pseudo-random*[Text Word] OR pseudo random*[Text
Word])
45. Search (control[Text Word] OR experiment*[Text Word] OR conservative[Text Word])) AND (treatment[Text Word] OR ther-
apy[Text Word] OR procedure[Text Word] OR manage*[Text Word])
46. Search (singl*[Text Word] OR doubl*[Text Word] OR tripl*[Text Word] OR trebl*[Text Word])) AND (blind*[Text Word] OR
mask*[Text Word])
47. Search (cross-over[Text Word]) OR cross over[Text Word]) OR crossover[Text Word])
48. Search (placebo*[Text Word] OR sham[Text Word])
49. Search trial[Title]
50. Search (assign*[Text Word] OR allocat*[Text Word])
51. Search controls[Text Word]
52. Search (#27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40
OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51)
53. Search (#13 AND #26 AND #52)
54. Search (“Animals”[Mesh]) NOT “Humans”[Mesh:noexp])
55. Search (#53 NOT #54)
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Appendix 3. Embase (Ovid) search strategy
Embase (Ovid) from 1974 to May 2016
1. CEREBROVASCULAR DISEASE/ or exp BASAL GANGLION DISEASE/ or exp BASAL GANGLION HEMORRHAGE/ or
exp BRAIN ISCHEMIA/ or exp CAROTID ARTERY DISEASE/ or exp CEREBROVASCULAR ACCIDENT/ or exp CEREBRAL
ARTERY DISEASE/ or exp BRAIN ARTERIOVENOUS MALFORMATION/ or exp BRAIN EMBOLISM/ or exp OCCLUSIVE
CEREBROVASCULAR DISEASE/ or exp BRAIN HEMORRHAGE/ or exp BRAIN INFARCTION/ or LACUNAR STROKE/ or
STROKE/ or BRAIN VASOSPASM/ or ARTERY DISSECTION/ or exp BRAIN HYPOXIA/
2. (stroke$ or post stroke or poststroke or post-stroke or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or SAH).ti,ab
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebr$ or mca$ or anterior circulation or basilar artery or vertebral artery) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$
or occlus$ or hypoxi$)).ti,ab.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or subarachnoid) adj5 (h?emorrhag$ or h?
ematoma$ or bleed$)).ti,ab
5. exp HEMIPLEGIA/ or exp PARESIS/ or exp APHASIA/ or exp NEUROLOGIC GAIT DISORDER/
6. (hemipar$ or hemipleg$ or paresis or paretic or aphasi$ or dysphasi$).ti,ab
7. exp BRAIN DAMAGE, CHRONIC/ or BRAIN INJURY/ or exp BRAIN CONCUSSION/ or exp BRAIN HAEMORRHAGE,
TRAUMATIC/ or BRAIN INJURY, CHRONIC/ or DIFFUSE AXONAL INJURY/
8. HEAD INJURY/ or exp HEAD INJURIES, CLOSED/ or exp INTRACRANIAL HEMORRHAGE, TRAUMATIC/
9. exp BRAIN ABSCESS/ or exp CENTRAL NERVOUS SYSTEM INFECTION/ or exp ENCEPHALITIS/ or exp MENINGITIS
10. (encephalitis or meningitis or head injur$).ti,ab.
11. exp BRAIN TUMOR/
12. ((brain or cerebr$) adj5 (injur$ or hypoxi$ or damage$ or concussion or trauma$ or neoplasm$ or lesion$ or tumor$ or tumour$
or cancer$ or infection$)).ti,ab.
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. DYSARTHRIA/ or SPEECH SOUND DISORDER/ or SPEECH ARTICULATION TESTS/
15. SPEECH DISORDER/ or VOICE DISORDER/ or APHONIA/ or DYSPHONIA/ or COMMUNICATION DISORDER/
16. (dysarth$ or dysphon$ or anarth$ or dyspros$ or aphon$ or dysfluen$ or stutter$ or stammer$).ti,ab
17. ((speech or articul$ or disarticul$ or phonat$ or phonolog$ or voice or vocal or prosod$ or intonat$ or respirat$ or communicat$
or fluen$) adj5 (disorder$ or impair$ or problem$ or difficult$)).ti,ab
18. (speech adj5 (slow$ or weak$ or imprecis$ or intelligibil$ or unintelligibil$ or accuracy or fatigue)).ti,ab
19. exp MOUTH/ or exp LARYNX/ or exp LARYNX MUSCLE/ or PHARYNX/ or exp PHARYNGEAL MUSCLE/ or FACE
MUSCLE/ or PALATE/
20. (mouth or tongue or lingual or palat$ or laryn$ or pharyn$ or orofacial or oro-facial or face musc$ or facial musc$).ti,ab
21. 19 or 20
22. MOTORDYSFUNCTION/ or ATAXIA/ or DYSTONICDISORDER/ or HYPERKINESIA/ or HYPOKINESIA/ orMUSCLE
HYPOTONIA/ or exp MUSCLE HYPOTONIA/ or MUSCLE WEAKNESS/ or MUSCLE DISEASE/ or SPASTICITY/
23. (atax$ or dyston$ or hyperkin$ or hypokin$ or hypoton$ or hyperton$ or flaccid$ or spastic$).ti,ab
24. 22 or 23
25. 21 and 24
26. 14 or 15 or 16 or 17 or 18 or 25
27. “RANDOMIZED CONTROLLED TRIAL (TOPIC)”/
28. RANDOMIZATION/
29. “CONTROLLED CLINICAL TRIAL (TOPIC)”/
30. CONTROL GROUP/
31. “CLINICAL TRIAL (TOPIC)”/ or “PHASE 1 CLINICAL TRIAL (TOPIC)”/ or “PHASE 2 CLINICAL TRIAL (TOPIC)”/ or
“PHASE 3 CLINICAL TRIAL (TOPIC)”/ or “PHASE 4 CLINICAL TRIAL (TOPIC)”/
32. DOUBLE BLIND PROCEDURE/
33. SINGLE BLIND PROCEDURE/
34. PLACEBO/
35. PLACEBO EFFECT/
36. CROSSOVER PROCEDURE/
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37. RANDOMIZED CONTROLLED TRIAL/
38. CLINICAL TRIAL/
39. PHASE 1 CLINICAL TRIAL/ or PHASE 2 CLINICAL TRIAL/ or PHASE 3 CLINICAL TRIAL/ or PHASE 4 CLINICAL
TRIAL/
40. (random$ or RCT or RCTs).ti,ab
41. (controlled adj5 (trial$ or stud$)).ti,ab
42. (clinical$ adj5 trial$).ti,ab.
43. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).ti,ab
44. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).ti,ab
45. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).ti,ab.
46. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab
47. (cross-over or cross over or crossover).ti,ab
48. (placebo$ or sham).ti,ab.
49. trial.ti
50. (assign$ or allocat$).ti,ab
51. controls.ti,ab.
52. 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48
or 49 or 50 or 51
53. 13 and 26 and 52
54. exp ANIMALS/ not HUMANS/
55. 53 not 54
Appendix 4. CINAHL (NICE Evidence Services Portal HDAS) search strategy
CINAHL (Ovid) from 1937 to May 2016
1. CEREBROVASCULAR DISORDERS/ OR exp BASAL GANGLIA CEREBROVASCULAR DISEASE/ OR exp HYPOXIA-
BRAIN,ISCHEMIA/ OR exp CAROTID ARTERY DISEASES/ OR exp CEREBROVASCULAR CIRCULATION/ OR exp IN-
TRACRANIAL ARTERIAL DISEASES/ OR exp ARTERIOVENOUS MALFORMATIONS/ OR exp INTRACRANIAL EM-
BOLISM AND THROMBOSIS/ OR exp INTRACRANIAL HEMORRHAGE/ OR STROKE/ OR STROKE,LACUNAR/ OR
CEREBRAL VASOSPASM/ OR VERTEBRAL ARTERY DISSECTIONS/ OR exp HYPOXIA,BRAIN
2. (stroke* OR “post stroke” OR poststroke OR post-stroke OR apoplex* OR “cerebral vasc*” OR cerebrovasc* OR cva OR SAHOR
“brain infarction” OR “cerebrovascular trauma”).ti,ab
3. ((brain OR cerebr* OR cerebell*OR vertebrobasil* OR hemispher* OR intracran* OR intracerebral OR infratentorial OR supraten-
torial OR “middle cerebr*” ORmca* OR “anterior circulation” OR “basilar artery” OR “vertebral artery”) adj5 (ischemi* OR ischaemi*
OR infarct* OR thrombo* OR emboli* OR occlus* OR hypoxi*)).ti,ab;
4. ((brain* OR cerebr* OR cerebell* OR intracerebral OR intracran* OR parenchymal OR intraparenchymal OR intraventricular
OR infratentorial OR supratentorial OR “basal gangli*” OR putaminal OR putamen OR “posterior fossa” OR hemispher* OR
subarachnoid) adj5 (hemorrhag* OR haemorrhag* OR hematoma* OR haematoma* OR bleed*)).ti,ab;
5. exp HEMIPLEGIA/ OR exp PARALYSIS/ OR exp APHASIA/ OR exp GAIT DISORDERS,NEUROLOGIC/;
6. (hemipar* OR hemipleg* OR paresis OR paretic OR aphasi* OR dysphasi*).ti,ab;
7. exp BRAIN DAMAGE,CHRONIC/ OR BRAIN INJURIES/ OR exp BRAIN CONCUSSION/ OR exp INTRACRANIAL
HEMORRHAGE/
8. (“chronic brain injury” OR “diffuse axonal injury” OR “craniocerebral trauma” OR “closed head injur*” OR “intracranial hemor-
rhag*”).ti,ab
9. exp BRAIN ABSCESS/ OR exp CENTRAL NERVOUS SYSTEM INFECTIONS/ OR exp ENCEPHALITIS/ OR exp MENIN-
GITIS/
10. (encephalitis OR meningitis OR “head injur*” OR “traumatic brain hemorrhag*” OR “chronic brain injury” OR “diffuse axonal
injury” OR “craniocerebral trauma” OR “closed head injur*” OR “intracranial hemorrhag*”).ti,ab
11. exp BRAIN NEOPLASMS/
12. ((brain OR cerebr*) adj5 (injur* OR hypoxi* OR damage* OR concussion OR trauma* OR neoplas* OR lesion* OR tumor* OR
tumour* OR cancer* OR infection*)).ti,ab
13. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12
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14. DYSARTHRIA/ OR ARTICULATION DISORDERS/ OR SPEECH ARTICULATION TESTS/
15. SPEECH DISORDERS/ OR VOICE DISORDERS/ OR APHONIA/ OR DYSPHONIA,SPASMODIC/ OR DYSPHO-
NIA,MUSCLE TENSION/ OR COMMUNICATIVE DISORDERS/
16. (dysarth* OR dysphon* OR anarth* OR dyspros* OR aphon* OR dysfluen* OR stutter* OR stammer*).ti,ab
17. ((speech OR articul* OR disarticul* OR phonat* OR phonolog* OR voice OR vocal OR prosod* OR intonat* OR respirat* OR
communicat* OR fluen*) adj5 (disorder* OR impair* OR problem* OR difficult*))
18. (speech adj5 (slow* OR weak* OR imprecis* OR intelligibil* OR unintelligibil* OR accuracy OR fatigue)).ti,ab
19. exp MOUTH/ OR exp LARYNX/ OR exp LARYNGEAL MUSCLES/ OR PHARYNX/ OR exp PHARYNGEAL MUSCLES/
OR FACIAL MUSCLES/ OR PALATAL MUSCLES/
20. (mouth OR tongue OR lingual OR palat* OR laryn* OR pharyn* OR orofacial OR oro-facial OR “face musc*” OR “facial
musc*”).ti,ab
21. 19 OR 20
22. MOVEMENT DISORDERS/ OR ATAXIA/ OR DYSTONIA/ OR DYSTONIC DISORDERS/ OR HYPERKINESIS/ OR
HYPOKINESIA/ORMUSCLEHYPOTONIA/ORexpMUSCLEHYPERTONIA/ORMUSCLEWEAKNESS/ORMUSCULAR
DISEASES/ OR MUSCLE SPASTICITY/
23. (atax* OR dyston* OR hyperkin* OR hypokin* OR hypoton* OR hyperton* OR flaccid* OR spastic*).ti,ab
24. 22 OR 23
25. 21 AND 24
26. 14 OR 15 OR 16 OR 17 OR 18 OR 25
27. RANDOMIZED CONTROLLED TRIALS/
28. RANDOM ASSIGNMENT/
29. CLINICAL TRIALS/
30. CONTROL GROUP/
31. (“clinical trials” OR “clinical trials,phase i” OR “clinical trials,phase ii” OR “clinical trials,phase iii” OR “clinical trials,phase
iv”).ti,ab
32. DOUBLE-BLIND STUDIES/
33. SINGLE-BLIND STUDIES/
34. PLACEBOS/
35. PLACEBO EFFECT/
36. CROSSOVER DESIGN/
37. “randomized controlled trial”.pt
38. “controlled clinical trial”.pt
39. (“clinical trial” OR “clinical trial phase i” OR “clinical trial phase ii” OR “clinical trial phase iii” OR “clinical trial phase iv”).pt
40. (random* OR RCT OR RCTs).ti,ab
41. (controlled adj5 (trial* OR stud*)).ti,ab
42. (clinical* adj5 trial*).ti,ab
43. ((control OR treatment OR experiment* OR intervention) adj5 (group* OR subject* OR patient*)).ti,ab
44. (quasi-random* OR “quasi random*” OR pseudo-random* OR “pseudo random*”).ti,ab
45. ((control OR experiment* OR conservative) adj5 (treatment OR therapy OR procedure OR manage*)).ti,ab
46. ((singl* OR doubl* OR tripl* OR trebl*) adj5 (blind* OR mask*)).ti,ab
47. (cross-over OR “cross over” OR crossover).ti,ab
48. (placebo* OR sham).ti,ab
49. trial.ti
50. (assign* OR allocat*).ti,ab
51. controls.ti,ab
52. 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR
44 OR 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51
53. 13 AND 26 AND 52
54. exp ANIMALS/ NOT HUMAN/
55. 53 NOT 54
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Appendix 5. PsycINFO search strategy
PsycINFO (Ovid) from 1800 to September 2016
1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular
accidents/ or subarachnoid hemorrhage/
2. (stroke$ or poststroke or apoplex$ or cerebral vasc$ or brain vasc$ or cerebrovasc$ or cva$ or SAH).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebral artery or MCA$ or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying)
adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or subarachnoid) adj5 (h?emorrhag$ or h?
ematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. head injuries/ or exp brain concussion/ or brain damage/ or exp traumatic brain injury/
8. ((brain or cerebr$) adj5 (injur$ or hypoxi$ or damage$ or concussion or trauma$ or neoplasm$ or lesion$ or tumor$ or tumour$
or cancer$ or infection$)).tw.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. dysarthria/ or articulation disorders/
11. dysphonia/ or speech disorders/
12. (dysarth$ or dyphon$ or anarth$ or dyspros$ or aphon$ or dysfluen$ or stutter$ or stammer$).tw.
13. ((speech or articul$ or disarticul$ or phonat$ or phonolog$ or voice or vocal or prosod$ or intonat$ or respirat$ or communicat$
or fluen$) adj5 (disorder$ or impair$ or problem$ or difficult$)).tw.
14. (speech adj5 (slow$ or weak$ or imprecis$ or intelligibil$ or unintelligibil$ or accuracy or fatigue)).tw.
15. “mouth (anatomy)”/ or exp tongue/ or larynx/ or pharynx/ or vocal cords/ or facial muscles/
16. (mouth or tongue or lingual or palat$ or laryn$ or pharyn$ or orofacial or oro-facial or face musc$ or facial musc$).tw.
17. 14 or 15
18. muscular disorders/ or movement disorders/ or ataxia/ or bradykinesia/ or dyskinesia/ or hyperkinesis/ or neuromuscular disorders/
or spasms/ or muscle spasms/
19. (atax$ or dyston$ or hyperkin$ or hypokin$ or hypoton$ or hyperton$ or flaccid$ or spastic$).tw.
20. 18 or 19
21. 17 and 20
22. 10 or 11 or 12 or 13 or 14 or 21
23. clinical trials/ or treatment effectiveness evaluation/ or placebo/
24. (random$ or RCT or RCTs).tw.
25. (controlled adj5 (trial$ or stud$)).tw.
26. (clinical$ adj5 trial$).tw.
27. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
28. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
29. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
30. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
31. (cross-over or cross over or crossover).tw.
32. (placebo$ or sham).tw.
33. trial.ti.
34. (assign$ or allocat$).tw.
35. controls.tw.
36. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
37. 9 and 22 and 36
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Appendix 6. Linguistics and Language Behavior Abstracts (LLBA) search strategy
LLBA (ProQuest) 1976 to November 2016
(((dysarth* OR dysphon* OR anarth* OR dyspros* OR aphon* OR dyston*) OR ((speech OR articulat* OR voice OR vocal OR
communicat*) AND (disorder* OR impair* OR problem* OR difficult*)) OR ((phonat* OR prosod* OR intonat* OR respirat*) AND
(disorder* OR impair* OR problem* OR difficult*)) OR SU(“Articulation Disorders” OR “Dysarthria”))) AND (SU(“Brain Damage”
OR “Stroke”) OR (stroke* OR “post stroke” OR poststroke OR post-stroke OR apoplex* OR cerebrovasc* OR CVA OR SAH OR
“cerebral vasc*”))
WH A T ’ S N E W
Last assessed as up-to-date: 6 May 2016.
Date Event Description
12 May 2016 New citation required and conclusions have changed This updated review has found that although the evidence
was not robust enough to indicatewhether one treatmentwas
better than another it does describe future research directions
in more detail
12 May 2016 New search has been performed The review title and scope of searches have been updated
since the last review. The review objectives have also been
amended since the review was last published. The previous
review found no studies suitable for inclusion. Five new stud-
ies (234 participants) have been included in the review. This
review includes risk of bias assessment, grading of the quality
of evidence and a ’Summary of findings’ table
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 2, 2001
Date Event Description
1 April 2015 Amended Amendments to update the protocol agreed with the Cochrane Stroke Group
Editorial Board
3 December 2014 Amended New first author and co-author team with previous lead author remaining
involved
2 October 2008 Amended Converted to new review format.
4 February 2005 New search has been performed All literature searches for this review have been updated. No new trials for
inclusion have been uncovered by these searches
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C O N T R I B U T I O N S O F A U T H O R S
Claire Mitchell initiated and designed the review, conducted the searches, screened and retrieved references, contacted relevant authors,
obtained translations for non-English publications, requested ongoing and unpublished study information, extracted data from included
trials, evaluated methodological quality, entered and analysed the data, interpreted the findings, and wrote the review. Audrey Bowen
designed the review, screened references for inclusion, extracted data from included trials, evaluated methodological quality, analysed
the data, interpreted the findings and contributed to the writing of the review. Sarah Tyson supported decision-making for inclusion,
contributed to the writing of the review, and commented on review drafts. Zoe Butterfint commented on the final versions of the
updated review. Paul Conroy designed the review, screened references for inclusion, extracted data from included trials, evaluated
methodological quality, analysed the data, interpreted the findings and contributed to the writing of the review.
D E C L A R A T I O N S O F I N T E R E S T
ClaireMitchell is a speech and language therapist and is funded by aNational Institute forHealth ResearchDoctoral Research Fellowship
(DRF-2014-07-043) and is registered with the Health and Care Professions Council, UK.
Audrey Bowen’s salary is part funded by Stroke Association and partly by the National Institute for Health Research Collaboration for
Leadership in Applied Health Research and Care (NIHR CLAHRC) Greater Manchester. Audrey Bowen has been involved in a study
included in this review (Bowen 2012). She did not contribute to the assessment or interpretation of this study.
Sarah Tyson: none known.
Zoe Butterfint: none known.
Paul Conroy is a speech and language therapist, member of the Royal College of Speech and Language Therapists, and is registered
with the Health and Care Professions Council, UK.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those
of the review authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
S O U R C E S O F S U P P O R T
Internal sources
• Jo Whitcombe (Clinical Outreach Librarian), Naomi Leech (Assistant Librarian) and Steven Glover (Head of Library Services)
Central Manchester University Hospitals NHS Foundation Trust, UK.
Search terms and searching
External sources
• National Institute for Health Research, UK.
Claire Mitchell is funded by a National Institute for Health Research Doctoral Research Fellowship DRF-2014-07-043
Audrey Bowen’s salary is part funded by Stroke Association and partly by the National Institute for Health Research Collaboration for
Leadership in Applied Health Research and Care (NIHR CLAHRC) Greater Manchester. The funders had no role in the design of
the study, data collection and analysis, decision to publish, or preparation of the manuscript. However, the project outlined in this
article may be considered to be affiliated to the work of the NIHR CLAHRC Greater Manchester.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title of this review was changed from “Speech and language therapy for dysarthria due to non-progressive brain damage” to reflect
the broader scope of the search, which is intended to have amore global reach. The search terms for this review now include interventions
carried out by any health professional, people with dysarthria, or a trained individual (whether voluntary, employed, or family member)
or any other possible approaches to delivery. This review has considered any type of intervention for acquired dysarthria including
behavioural or psychological approaches, use of devices and medication, with the exception of surgical intervention. This review was
also designed to reflect the international levels of functioning including impairment, activity, and participation level effects (WHO
2001). We included an examination of risk of bias in this review in accordance with current Cochrane methodology (Higgins 2011).
This review now has a summary of findings table which includes the five GRADE considerations to assess the quality of the body of
evidence of the studies included in the meta-analysis using GRADEproGDT software (GRADEproGDT 2015). The primary outcome
in the protocol was to examine long-term, persistent effectiveness between three and nine months post-intervention, but during the
review process, we found this time criterion was too restrictive. Following discussion among review authors the timings were relaxed to
include Mackenzie 2014, which was felt to be the most appropriate way forward, but this was a change from the original protocol.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Language Therapy; ∗Speech Therapy; Brain Injury, Chronic [complications]; Dysarthria [etiology; ∗therapy]; Stroke [complications]
MeSH check words
Adult; Humans
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